Severe mental disorder with onset in MIDDLE AGE, marked by withdrawal, abnormal affect, disturbed intellectual processes, and there may be regression.
| Excerpt | Reference |
|---|
| "Major depressive disorder is frequently a chronic, recurrent condition necessitating maintenance treatment." | ( Brown, EB; Gonzales, JS; Miner, CM; Munir, R, 2002) |
| "Major depressive disorder is associated with considerable morbidity, disability, and risk for suicide." | ( Dunner, DL; Heim, CM; Keitner, G; Keller, MB; Klein, DN; Kornstein, S; McCullough, JP; Nemeroff, CB; Ninan, PT; Rothbaum, BO; Rush, AJ; Schatzberg, AF; Thase, ME; Weiss, PM, 2003) |
| "Since major depressive disorder is also associated with alterations in serum cytokine concentrations, the authors hypothesized that bone loss in patients with major depressive disorder and comorbid borderline personality disorder may be associated with cytokines capable of activating osteoclastic cells." | ( Dibbelt, L; Gehl, HB; Hohagen, F; Kahl, KG; Markhof, K; Rudolf, S; Schweiger, U; Stoeckelhuber, BM, 2005) |
| "Major depressive disorder is a common, chronic, recurring, and disabling illness in children and adolescents." | ( Emslie, GJ; Ryan, ND; Wagner, KD, 2005) |
| "Subsyndromal major depressive disorder is common among HIV-positive adults." | ( Ferrando, SJ; McElhiney, MC; McGrath, PJ; Rabkin, JG; Rabkin, R, 2006) |
| "Major depressive disorder is characterized by increased and sustained emotional reactivity, which has been linked to sustained amygdala activity." | ( Carter, CS; Siegle, GJ; Steinhauer, SR; Thase, ME; Thompson, W, 2007) |
| "Major depressive disorder is a recurrent illness that often requires maintenance antidepressant treatment." | ( Bose, A; Gandhi, C; Kornstein, SG; Li, D; Saikali, KG, 2006) |
| "Major depressive disorder is a difficult-to-treat and recurrent debilitating disorder." | ( Goforth, HW; Holsinger, T, 2007) |
| "Major depressive disorder is a worrying mental health problem and obtaining remission from treatment resistant depression (TRD) remains an important clinical issue." | ( Aubry, JM; Bertschy, G; Bondolfi, G; Gervasoni, N; Gex-Fabry, M, 2009) |
| "Major depressive disorder is characterized by impaired reward processing, possibly due to dysfunction in the basal ganglia." | ( Birk, JL; Bogdan, R; Dillon, DG; Dougherty, DD; Fava, M; Goetz, EL; Holmes, AJ; Iosifescu, DV; Pizzagalli, DA; Rauch, SL, 2009) |
| "Major depressive disorder is associated with increased cardiac mortality." | ( Bär, KJ; Höfels, S; Maier, W; Schuhmacher, A; Schulz, S; Voss, A; Yeragani, VK; Zobel, A, 2010) |
| "Major depressive disorder is associated with dysregulated basal cortisol levels and small hippocampal (HC) volume." | ( Andrews, J; Beaudry, T; Dedovic, K; Duchesne, A; Efanov, SI; Engert, V; Lue, SD; Pruessner, JC, 2010) |
| "Major depressive disorder is associated with alterations in the neuroendocrine as well as immune system." | ( Balk, FJ; Denys, DA; Fluitman, SB; Heijnen, CJ; Nolen, WA; Westenberg, HG, 2011) |
| "Major depressive disorder is a disease whose course is often chronic because the prevalence of recurrence is high." | ( Courtet, P; Olié, E, 2010) |
| "Major depressive disorder is a chronic disabling disease, often triggered and exacerbated by stressors of a social nature." | ( Hoogendijk, WJ; Lucassen, PJ; Oomen, CA; Smit, AB; Spijker, S; Van Bokhoven, P, 2011) |
| "Major depressive disorder is a prevalent disease, and current pharmacotherapy is considered to be inadequate." | ( Bymaster, FP; Golembiowska, K; Kowalska, M, 2012) |
| "Major depressive disorder is among the most prevalent forms of mental illness." | ( Ago, Y; Chaki, S; Matrisciano, F; Palucha-Paniewiera, A; Pilc, A, 2013) |
| "Major depressive disorder is a chronic, remitting syndrome involving widely distributed circuits in the brain." | ( Kennedy, PJ; Nestler, EJ; Sun, H, 2013) |
| "Major depressive disorder is one of the most prevalent psychiatric disorders, and in spite of extensive ongoing research, we neither fully understand its etiopathological background, nor do we possess sufficient pharmacotherapeutic tools to provide remission for all patients." | ( Dome, P; Faludi, G; Gonda, X; Weizman, S, 2012) |
| "Bipolar and major depressive disorders are essentially relapsing and remitting disorders of affect with nearly full recovery between episodes." | ( Hayashi, Y; Ikeda, K; Nihonmatsu-Kikuchi, N; Soma, M; Tatebayashi, Y; Yu, X, 2012) |
| "Major depressive disorder is an extremely debilitating condition affecting millions of people worldwide." | ( Cattaneo, A; Horowitz, MA; Lupi, MM; Pariante, CM; Zunszain, PA, 2013) |
| "Major depressive disorder is associated with significant impairment in occupational functioning and reduced productivity, which represents a large part of the overall burden of depression." | ( Axler, A; Kennedy, SH; Lam, RW; Manjunath, CV; Michalak, EE; Parikh, SV; Ramasubbu, R; Tam, EM; Yatham, LN, 2013) |
| "Major depressive disorder is a common psychiatric illness with reported prevalence rates of 12-16% in persons aged 12 and over." | ( De Long, NE; Hardy, DB; Holloway, AC; Hyslop, JR; Raha, S, 2014) |
| "Major depressive disorder is the most common mood disorder in the United States and European Union; however, the limitations of clinically available antidepressant drugs have led researchers to pursue novel pharmacological treatments." | ( Hillhouse, TM; Keiser, AA; Matazel, KS; Prus, AJ; Shankland, Z, 2014) |
| "Major depressive disorder is a highly prevalent and debilitating condition in youth, so developing efficient treatments is a priority for mental health professionals." | ( David, D; Iftene, F; Predescu, E; Stefan, S, 2015) |
| "Major depressive disorder is a common consequence of exposure to the pro-inflammatory cytokine interferon alpha, which is treated effectively with antidepressant medication." | ( Burridge, A; Fialho, R; File, A; Keller, M; Pereira, M; Tibble, J; Whale, R, 2016) |
| "Major depressive disorder is a devastating mental illness leading to a lifetime prevalence of higher than 16% on individuals." | ( Pei, LB; Wen, ZY; Yang, JL; Yu, JJ; Zhang, Y, 2015) |
| "Major depressive disorder is characterized by anhedonia, cognitive biases, ruminations, hopelessness and increased anxiety." | ( Christmas, D; Gradin, V; Johnston, BA; Matthews, K; Steele, JD; Tolomeo, S, 2015) |
| "Major depressive disorder is often accompanied by elevated levels of anger, hostility, and irritability, which may contribute to worse outcomes." | ( Alpert, JE; Doros, GD; Fava, M; Fisher, LB; Freeman, MP; Henry, M; Huz, I, 2015) |
| "Major depressive disorder is common among women in child-bearing age, and medical treatment is subject to substantial discussions and controversies." | ( Damkier, P; Ennis, ZN; Lassen, D, 2016) |
| "Major depressive disorder is characterized as persistent low mood." | ( Cui, S; Wang, JH; Xu, A, 2016) |
| "Major depressive disorder is increasingly recognized to involve functional deficits in both gamma-aminobutyric acid (GABA)ergic and glutamatergic synaptic transmission." | ( Fuchs, T; Jefferson, SJ; Luscher, B; Pribiag, H; Ren, Z; Shorey, M; Stellwagen, D, 2016) |
| "Major depressive disorder is one of the most common mental disorders in children and adolescents." | ( Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X, 2016) |
| "Major depressive disorder is one of the most common diseases in western countries." | ( Edwards, MJ; Grassmé, H; Gulbins, A; Gulbins, E; Hoehn, R; Kohnen, M; Kornhuber, J; Soddemann, M; Wilker, B, 2016) |
| "Major depressive disorder is the most common psychiatric disorder with lifetime prevalence of up to 20% worldwide." | ( Freitas, AE; Neis, VB; Rodrigues, ALS, 2016) |
| "Major depressive disorder is a serious and devastating psychiatric disorder." | ( Deng, R; Fan, Y; Li, K; Li, X; Liu, QS; Liu, R; Meng, F, 2017) |
| "Major depressive disorder is a complex clinical entity, including different molecular mechanisms and neurological processes." | ( Filipek, B; Jakubczyk, M; Lustyk, K; Młyniec, K; Podkowa, A; Podkowa, K; Pytka, K; Sapa, J; Żmudzka, E, 2017) |
| "Major depressive disorder is a severe and complex mental disorder." | ( Huang, YJ; Lane, HY; Lin, CH, 2017) |
| "Major depressive disorder is a debilitating illness, which is most commonly treated with antidepressant drugs." | ( Berlim, M; Chachamovich, E; Fiori, LM; Foster, J; Jollant, F; Kennedy, SH; Lopez, JP; Richard-Devantoy, S; Rotzinger, S; Turecki, G, 2017) |
| "Major depressive disorder is a common mental disorder affecting a person's mind, behaviour and body." | ( Barbui, C; Breilmann, J; Guaiana, G; Koesters, M; Ostuzzi, G, 2017) |
| "Major depressive disorder is associated with raised peripheral inflammatory markers." | ( Anton-Rodriguez, JM; Conen, S; Gerhard, A; Gregory, CJ; Hinz, R; Holmes, SE; Matthews, JC; Talbot, PS, 2018) |
| "Major depressive disorder is a frequent and devastating psychological condition with tremendous public health impact." | ( Vutskits, L, 2018) |
| "Major depressive disorder is a psychiatric disorder that affects 4." | ( Costa, EA; da Rocha, FF; da Silva, DM; da Silva, DPB; de Brito, AF; de Oliveira, DR; Fajemiroye, JO; Florentino, IF; Galdino, PM, 2018) |
| "Major depressive disorders are characterized by their severity and long-lasting symptoms, which make such disorders highly disabling illnesses." | ( Berumen, LC; García-Alcocer, G; López-Vallejo, F; Miledi, R; Padilla, KM; Quintanar-Setephano, A, 2018) |
| "Major depressive disorder is a common but devastating mental disorder, and recent evidence shows that neuroinflammation may play a pivotal role in the etiology of depression." | ( Deng, J; Ma, SP; Ma, ZQ; Ruan, J; Song, MT; Zhang, RY, 2018) |
| "Major depressive disorder is a common and debilitating condition with substantial economic impact." | ( Andersson, M; Bergström, N; Culley, G; Ehn, J; Engström, A; Hanse, E; Karlsson, L; Kuhn, HG; Michaëlsson, H; Savvidi, P; Seth, H; Svensson, J, 2019) |
| "Major depressive disorder is a severe, disabling disorder that affects around 4." | ( Berrocoso, E; González-Saiz, F; Mico, JA; Perez-Caballero, L; Romero-López-Alberca, C; Torres-Sanchez, S, 2019) |
| "Major depressive disorder is a prevalent and life-threatening illness in modern society." | ( Fan, M; Huang, Z; Jin, X; Lai, S; Li, M; Liang, J; Liu, Y; Shang, Y; Song, Y; Xiao, K; Yu, H; Zhang, J; Zhi, X, 2019) |
| "Major depressive disorders are emerging health problems that affect millions of people worldwide." | ( Chen, WW; Fang, WQ; Fu, AKY; Fu, WY; Ip, NY; Su, YT, 2019) |
| "The etiology of major depressive disorder is heterogeneous, and differing pathways leading to the development of depression are proposed to account for alternative variants of depressive illness and their distinct comorbidity patterns." | ( Bowyer, CB; Hajcak, G; Joyner, KJ; Patrick, CJ; Venables, NC; Yancey, JR, 2019) |
| "Major depressive disorder is a heterogeneous disease involving widespread disruptions in functional brain networks, the neurobiological mechanisms of which are poorly understood." | ( Chen, G; Felger, JC; Haroon, E; Li, Z; Luo, Y; Mehta, ND; Miller, AH; Xu, X; Yin, L, 2019) |
| "Major depressive disorder is a complex multifactorial condition with a so far poorly characterized underlying pathophysiology." | ( Abdel-Ahad, P; Blatzer, M; Callebert, J; Chrétien, F; Danckaert, A; de Maricourt, P; De Medeiros, GF; Gaillard, R; Jouvion, G; Langeron, O; Launay, JM; Maignan, A; Petit, AC; Sharshar, T; Van Steenwinckel, J; Verdonk, F; Vinckier, F, 2019) |
| "Major depressive disorder is one of the most important psychiatric issues worldwide, with important prevalence of treatment-resistant depression (TRD)." | ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Szarmach, J; Szałach, ŁP; Słupska, A; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczyk, A, 2019) |
| "Major depressive disorder is associated with aberrant resting-state functional connectivity across multiple brain networks supporting emotion processing, executive function, and reward processing." | ( Adams, P; Carmody, T; Chin Fatt, CR; Cooper, CM; Etkin, A; Fava, M; Fonzo, G; Grannemann, B; Greer, TL; Jha, MK; Kurian, B; McGrath, PJ; McInnis, M; Parsey, RV; Phillips, ML; South, C; Trivedi, MH; Weissman, M, 2020) |
| "Major depressive disorder is associated with altered social functioning and impaired learning, on both the behavioural and the neural level." | ( Frey, AL; McCabe, C, 2020) |
| "Major depressive disorder is a serious neuropsychiatric disease that leads to significant impairment in social functioning and increased morbidity and mortality." | ( Alghamdi, S; Alsufiani, H; Alsulami, N; Khoja, S; Tarazi, FI; Tayeb, HO, 2020) |
| "Major depressive disorder is associated with abnormal functioning of the hypothalamic-pituitary-adrenal (HPA) axis." | ( Cui, L; Cui, W; Li, T; Ma, X; Peng, Z; Song, X; Yu, X; Zhao, L, 2020) |
| "Major depressive disorder is characterized by the presence of at least five of nine specific symptoms that contribute to clinically significant functional impairment." | ( Boucher, M; Katzman, MA; Wajsbrot, DB; Wang, X, 2020) |
| "Major depressive disorder is among main worldwide causes of disability." | ( Amini, M; Hosseinzadeh, M; Khosravi, M; Mansoori, A; Raisi, F; Sotoudeh, G, 2020) |
| "Major depressive disorder is a leading cause of disability and significant mortality, yet mechanistic understanding remains limited." | ( Campbell, A; Delgado, MR; Harris, MA; Hawkins, E; Hirose, Y; Lawrie, SM; Macfarlane, JA; McIntosh, AM; McNeil, CJ; Murray, AD; Porteous, D; Romaniuk, L; Rupprechter, S; Sandu, AL; Series, P; Shen, X; Steele, JD; Waiter, GD; Whalley, HC, 2020) |
| "Major depressive disorder is most commonly treated with a combination of medication and psychotherapy." | ( Stengler, M, 2021) |
| "Major depressive disorder is a highly debilitating psychiatric disorder and is considered to be a disabling public health problem, worldwide, as a primary factor associated with suicide." | ( da Silva Calixto, P; de Almeida, RN; Dos Santos Maia, M; Filho, JMB; Scotti, L; Scotti, MT; Stiebbe Salvadori, MGS, 2021) |
| "Major depressive disorder is associated with abnormal connectivity across emotion and reward circuits as well as other established circuits that may negatively impact treatment response." | ( Aslan, S; Chin Fatt, CR; Cooper, C; Etkin, A; Fava, M; Grannemann, B; Greer, TL; Jha, MK; Kurian, B; McGrath, PJ; Parsey, RV; Phillips, ML; Trivedi, MH; Weissman, M, 2021) |
| "Major depressive disorder is a common debilitating mental health problem that represents one of the leading causes of disability." | ( Belzung, C; Brizard, B; Eliwa, H; Hen, R; Le Guisquet, AM; Surget, A, 2021) |
| "Major depressive disorder is the most prevalent mental illness worldwide, still its pharmacological treatment is limited by various challenges, such as the large heterogeneity in treatment response and the lack of insight into the neurobiological pathways underlying this phenomenon." | ( Hasch, A; Herzog, DP; Jene, T; Lieb, K; Lutz, B; Müller, MB; Opitz, V; Pascual Cuadrado, D; Sillaber, I; Tiwari, VK; Treccani, G; van der Kooij, MA, 2021) |
| "Major depressive disorder is one of the leading global causes of disability, for which the classic serotonergic psychedelics have recently reemerged as a potential therapeutic treatment option." | ( de Manincor, M; Galvão-Coelho, NL; Gonzalez, M; Marx, W; Perkins, D; Sarris, J; Sinclair, J, 2021) |
| "A core feature of major depressive disorder is a loss of interest in previously rewarding activities." | ( Donaldson, LF; Lumb, BM; Phelps, CE; Robinson, ES, 2021) |
| "Major depressive disorder is a genetic susceptible disease, and a psychiatric syndrome with a high rate of incidence and recurrence." | ( Botchway, BOA; Chen, S; Fang, L; Fang, M; Hu, Y; Hu, Z; Tan, X; Xie, S, 2022) |
| "Major depressive disorder is caused by gene-environment interactions, and the host microbiome has been recognized as an important environmental factor." | ( Fang, L; Ji, P; Li, W; Liu, L; Pu, J; Rao, X; Song, J; Wang, H; Wei, H; Xie, P; Yang, D; Yu, Y; Zhao, L; Zheng, P; Zhou, C, 2021) |
| "Major depressive disorder is one of the most common, burdensome, and costly psychiatric disorders worldwide." | ( Barbateskovic, M; Gluud, C; Hengartner, MP; Jakobsen, JC; Juul, S; Jørgensen, CK; Kirsch, I; Siddiqui, F, 2021) |
| "Major depressive disorder is prevalent in children and adolescents and is associated with a high degree of morbidity throughout life, with potentially devastating personal consequences and public health impact." | ( Bolaños-Guzmán, CA; Cardona-Acosta, AM; Chaudhury, D; Gyles, TM; Han, MH; Juarez, B; Nestler, EJ; Parise, EM; Parise, LF; Sial, OK, 2021) |
| "Major depressive disorder is a common, recurrent illness." | ( Chen, BK; Denny, CA; Hunsberger, HC; Luna, VM; Mastrodonato, A; McGowan, JC; Rubinstenn, G; Shannon, ME; Stackmann, M, 2021) |
| "Major depressive disorder is prevalent and impairing." | ( Brown, VM; Chiu, PH; King-Casas, B; McCurry, KL; Solway, A; Wang, JM; Zhu, L, 2021) |
| "Major depressive disorder is also highly comorbid in this population, leading to further impairment." | ( Goldschmied, JR; Kayser, MS; Morales, KH; Sengupta, A; Sharma, A; Taylor, L; Thase, ME; Weljie, A, 2021) |
| "Major depressive disorder is a severe illness that frequently manifests before the age of 18 years, often recurring later in life." | ( Arango, C; Buitelaar, JK; Chimits, D; Falissard, B; Fegert, JM; Marx, U; Olivier, V; Pénélaud, PF, 2022) |
| "Major depressive disorder is the leading cause of disability worldwide." | ( Farooq, RK; Hanif, R; Javed, A; Nasir, S; Nazir, S, 2022) |
| "Major depressive disorder is the most common mood disorder in the United States today and the need for adequate treatment has been universally desired for over a century." | ( Luijk, MPCM; van der Horst, FCP; van Rosmalen, L, 2022) |
| "Major depressive disorder is the most common neuropsychiatric comorbidity of human immunodeficiency virus (HIV), and women are more frequently affected in the general population and among those with HIV." | ( Bakker, CJ; Lofgren, SM; Spencer, SM; Turk, MC, 2022) |
| "Major depressive disorder is one of the most common mental disorders, and more than 300 million of people suffer from depression worldwide." | ( Coenen, VA; Döbrössy, MD; Pfeiffer, L; Serchov, T; Tong, Y, 2022) |
| "Major depressive disorder is a devastating psychiatric illness that affects approximately 17% of the population worldwide." | ( Cao, X; Chen, LY; Fan, J; Fang, YY; Gao, TM; Guo, F; Li, SJ; Li, YL; Lu, CL; Mo, JW; Ren, J; Wen, YL; Wu, ZF, 2022) |
| "Major depressive disorder is a prevalent and heterogeneous disorder with treatment resistance in at least 50% of individuals." | ( Abdallah, C; Esterlis, I; Holmes, SE, 2023) |
| "Major depressive disorder is a highly prevalent psychiatric condition." | ( Breviario, S; Castro, E; Díaz, Á; Florensa-Zanuy, E; Garro-Martínez, E; Pazos, Á; Pilar-Cuéllar, F; Senserrich, J, 2023) |
| "Major depressive disorder is one of the primary causes of disability and disease worldwide." | ( Carboni, E; Carta, AR, 2022) |
| "Major depressive disorder is a prevalent mood illness that is mildly heritable." | ( Alamri, A; Alamri, AS; Alhabeeb, AA; Alhomrani, M; Alkhatabi, HA; Alsanie, WF; Alyami, H; Felimban, RI; Gaber, A; Habeeballah, H; Raafat, BM; Refat, MS; Shakya, S, 2022) |
| "Major depressive disorder is a burdensome condition with few treatment options, and traditional antidepressants are characterized by slow onset." | ( Chen, S; Hong, W; Huang, H; Lyu, D; Shi, S; Wang, F; Wang, M; Wei, Z; Xu, Y; Yang, W; Zhang, M, 2022) |
| "Major depressive disorder is a highly common disorder, with a lifetime prevalence in the United States of approximately 21%." | ( Burgess, GE; Dripps, IJ; Hallahan, JE; Hillhouse, TM; Jutkiewicz, EM; Ladetto, AG; Olson, KM; Rice, KC; Traynor, JR; West, JL, 2023) |
| "Major depressive disorder is a highly common disorder, with a lifetime prevalence in the United States of approximately 21%." | ( Burgess, GE; Dripps, IJ; Hallahan, JE; Hillhouse, TM; Jutkiewicz, EM; Ladetto, AG; Olson, KM; Rice, KC; Traynor, JR; West, JL, 2023) |
| "Major depressive disorder is considered one of the most frequent diseases in the general population, and treatment-resistant depression (TRD) represents the subset with more significant clinical and social impact." | ( Armeni, P; Costa, F; Falivena, C; Rognoni, C, 2023) |
| "Major depressive disorder is a frequently occurring neuropsychiatric disorder throughout the world." | ( Chen, WJ; Chen, YM; Fan, H; Guan, W; Huang, J; Jiang, B; Li, WY; Liu, JF; Shi, TS; Wang, CN; Zhu, BL, 2023) |
| "Major depressive disorder is the most common type of mental disorder." | ( Alt, R; da Cunha, LL; Feter, N; Rombaldi, AJ, 2023) |
| "Major depressive disorder is a common and devastating psychiatric disease, and the prevalence and burden are substantially increasing worldwide." | ( Cao, X; Chen, LY; Fan, J; Fang, YY; Gao, TM; Gu, TT; Guo, F; Kuang, XJ; Li, SJ; Liu, JM; Lu, CL; Mo, JW; Mo, R; Ren, J; Wen, YL; Zhao, C; Zhong, QL, 2023) |
| "Major depressive disorder is a highly prevalent psychiatric disorder." | ( Al-Sharif, NB; Espinoza, RT; Leaver, AM; Narr, KL; Sahib, AK; Taraku, B; Zavaliangos-Petropulu, A, 2023) |
| "Major depressive disorder is a heterogeneous syndrome, of which the most common subtype is melancholic depression (MEL)." | ( Bai, T; Jiang, Y; Tian, Y; Wang, K; Xie, X; Zhang, M; Zhang, T, 2023) |
| "Major depressive disorder is a common psychiatric disorder, with ∼30% of patients suffering from treatment-resistant depression." | ( Deng, W; Guo, W; Hu, X; Li, T; Luo, X; Ma, X; Ni, P; Qi, X; Wang, Q; Wei, L; Wei, Y; Yu, X; Zhao, L; Zheng, Y, 2023) |
| "Major depressive disorder is often associated with worsened reward learning, with blunted reward response persisting after remission." | ( Aizenstein, HJ; George, CJ; Karim, HT; Kolobaric, A; Kovacs, M; Mizuno, A; Seidman, A; Yang, X, 2023) |
| "Major depressive disorder is one of the most common mental illnesses that highly impairs quality of life." | ( Jazvinšćak Jembrek, M; Karlović, D; Oršolić, N; Peitl, V, 2023) |
| "Major depressive disorder is a frequent and debilitating psychiatric disease." | ( Illes, P; Li, J; Ren, WJ; Rubini, P; Tang, Y; Yuan, ZQ; Zhao, YF, 2023) |
| "Major depressive disorder is a serious psychiatric illness having serious damaging effect on the quality of life of suffers." | ( Abubakar, B; Adeniyi, FR; Adeoluwa, GO; Adeoluwa, OA; Akinluyi, ET; Edem, EE; Eduviere, AT; Fafure, A; Nebo, K; Olayinka, JN, 2023) |
| "Major depressive disorder is frequently characterized by disinhibition of rapid eye movement (REM) sleep and disruption of non-REM (NREM) sleep." | ( Bagdy, G; Koncz, S; Papp, N; Pothorszki, D, 2023) |
| "Major depressive disorder is one of the most common psychiatric disorders in the world." | ( Hedayati, A; Hosseini, FA; Shaygan, M; Shemiran, M, 2023) |
| "Major Depressive Disorder is the leading cause of disability worldwide." | ( Galán-Armenteros, RM; González-González, C; Marco-Feced, MA; Moreno-Campos, AJ; Romero-Mohedano, MC, 2023) |
| "MDD (major depressive disorder) is a highly prevalent mental disorder with a complex etiology involving behavioral and neurochemical factors as well as environmental stress." | ( Białek, K; Czarny, PL; Gałecki, P; Kołodziej, Ł; Śliwiński, T; Su, KP; Szemraj, J; Ziółkowska, S, 2023) |
| "Major depressive disorder is often resistant to first-line treatment, with around 30% failing to respond to traditional therapy." | ( Anil, A; Chattu, SK; Chattu, VK; Dwivedi, P; Manna, S; Padhi, BK; Sah, R; Sahoo, S; Saravanan, A; Satapathy, P; Shamim, MA; Shukla, R; Singh, S; Srivastav, S; Swami, MK; Thaper, K; Varthya, SB, 2023) |
| Excerpt | Reference |
|---|
| "For depressive neurosis and involutional melancholia best therapeutic responses were yielded at a dosage of 50 mg, while in the treatment of manic-depressive illness, comparable results occurred at a 150 mg dosage." | ( Corona, GL; Cucchi, ML; Fenoglio, L; Frattini, P; Pinelli, P; Santagostino, G; Zerbi, F, 1980) |
| "The authors attempted to treat Major Depressive Disorder (MDD) suboptimally responsive to one of the newer (second-generation) antidepressants by augmentation with a psychostimulant medication." | ( Anand, VS; Masand, PS; Tanquary, JF, 1998) |
| "Ninety-one outpatients with DSM-IV major depressive disorder who had a 17-item Hamilton Depression Rating Scale (HAM-D) score > or = 18 were treated with open label sertraline for 3 weeks." | ( Demartinis, N; García-España, F; Mandos, LA; Rickels, K; Rynn, M; Schweizer, E, 2001) |
| "Patients (N=102) meeting criteria for major depressive disorder were randomly assigned to one of these three treatments for 16 to 20 therapy sessions." | ( Coon, DW; Gallagher-Thompson, D; Koin, D; Sommer, BR; Thompson, LW, 2001) |
| "Patients with chronic forms of major depressive disorder were randomized to 12 weeks of nefazodone, Cognitive Behavioral Analysis System of Psychotherapy (CBASP), or combined nefazodone/CBASP." | ( Borian, FE; Crits-Christoph, P; Dunner, DL; Hirschfeld, RM; Keitner, G; Keller, MB; Klein, DN; Koran, LM; Kornstein, SG; Markowitz, JC; Miller, I; Nemeroff, CB; Ninan, PT; Rush, AJ; Schatzberg, AF; Thase, ME; Trivedi, MH, 2002) |
| "Patients (N = 284) with DSM-IV major depressive disorder were randomly assigned in a double-blind fashion to fluoxetine, paroxetine, or sertraline for 10 to 16 weeks of treatment." | ( Fava, M; Gonzales, JS; Hoog, SL; Judge, RA; Kopp, JB; Nilsson, ME, 2002) |
| "Patients had met DSM-IV criteria for major depressive disorder prior to beginning treatment for their current episode, had received 6 to 52 weeks of treatment with citalopram (20-40 mg/day [N = 83]), paroxetine (20 mg/day [N = 77]), or sertraline (50-100 mg/day [N = 86]), and had responded to that treatment (Clinical Global Impressions-Severity of Illness [CGI-S] score < or = 2, modified 17-item Hamilton Rating Scale for Depression [HAM-D-17] score < or = 10)." | ( Brown, EB; Gonzales, JS; Miner, CM; Munir, R, 2002) |
| "Twenty-five consenting patients with major depressive disorders underwent 100 maintenance ECT treatments." | ( Litle, M; Rawal, S; Recart, A; Stool, L; Thornton, L; White, PF, 2003) |
| "Patients with major depressive disorder (MDD) may have significant differences in cholesterol levels compared with healthy adults, while MDD patients with elevated cholesterol have a poorer prognosis for treatment response." | ( Alpert, JE; Fava, M; Hughes, ME; Mischoulon, D; Nierenberg, AA; Papakostas, GI; Petersen, T; Rosenbaum, JF, 2003) |
| "Up to 50% of patients with major depressive disorder (MDD) fail to respond to an antidepressant trial, with most taking a selective serotonin reuptake inhibitor (SSRI) as an initial treatment." | ( Fava, M; Mahal, Y; McGrath, P; Papakostas, GI; Petersen, T; Quitkin, F; Stewart, J, 2003) |
| "The treatment of patients with major depressive disorder has advanced tremendously in the past decade as a result of the availability of effective and well-tolerated antidepressants." | ( Keller, MB, 2003) |
| "Forty-seven patients with major depressive disorder, randomized to double-blind treatment with sertraline or placebo, completed sleep studies before and after 12 weeks of pharmacotherapy." | ( Berman, SR; Fasiczka, AL; Friedman, ES; Howland, RH; Jindal, RD; Thase, ME, 2003) |
| "Functional imaging studies of major depressive disorder demonstrate response-specific regional changes following various modes of antidepressant treatment." | ( Bieling, P; Garson, C; Goldapple, K; Kennedy, S; Lau, M; Mayberg, H; Segal, Z, 2004) |
| "Fifty-two patients with major depressive disorder (MDD) based on DSM-IV criteria along with comorbid HM were allotted to an 8 week trial with a flexible-dose regime of paroxetine in combination with their chemotherapy or supportive pharmacotherapy." | ( Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Lee, C; Lee, CU; Lee, S; Lee, SJ; Min, WS; Pae, CU; Paik, IH; Serretti, A; Won, WY, 2004) |
| "Twenty patients with major depressive disorder (MDD) who had failed to experience a clinical response to an adequate trial of an SSRI were treated with open-label ziprasidone in addition to their SSRI for 6 weeks between February 2002 and December 2002." | ( Alpert, JE; Fava, M; Murakami, JL; Nierenberg, AA; Papakostas, GI; Petersen, TJ; Rosenbaum, JF, 2004) |
| "Patients with DSM-IV major depressive disorder who had not responded to at least 1 previous antidepressant and at least 6 weeks of treatment with citalopram or bupropion-SR were treated in a standard clinical protocol." | ( Hossie, H; Lam, RW; Solomons, K; Yatham, LN, 2004) |
| "Patients with a history of ED when major depressive disorder (MDD) was diagnosed, which persisted after MDD was treated to remission, were randomized to 12 weeks of treatment with sildenafil (50 mg, flexible) or placebo." | ( Furlan, PM; Gomez-Beneyto, M; Opsomer, R; Schreiber, W; Sweeney, M; Tignol, J; Wohlhuter, C, 2004) |
| "Fifty-one subjects with major depressive disorder (MDD) were enrolled in a 1-week single blind placebo lead-in, followed by an 8-week, double-blind placebo-controlled treatment with either fluoxetine or venlafaxine." | ( Azen, SP; Chou, CP; James Gauderman, W; Leuchter, AF; Marie-Mitchell, A, 2004) |
| "Initial treatment of major depressive disorder in adolescents may include cognitive-behavioral therapy (CBT) or a selective serotonin reuptake inhibitor (SSRI)." | ( Burns, B; Curry, J; Domino, M; Fairbank, J; March, J; McNulty, S; Petrycki, S; Severe, J; Silva, S; Vitiello, B; Wells, K, 2004) |
| "In 19 patients with major depressive disorder, effective treatment with selective serotonin reuptake inhibitors (SSRIs) or amesergide (AMSG) was associated with increased cerebral perfusion in anterior cingulate cortex (SSRI and AMSG) and in medial prefrontal cortex (AMSG)." | ( Fischer, K; Mintun, MA; Sheline, YI; Vlassenko, A, 2004) |
| "One hundred thirteen patients with major depressive disorder were randomly assigned to 8 wk of double-blind outpatient treatment with low-dose T3 (25 microg), high-dose T3 (25 microg twice daily), or placebo in addition to paroxetine 30 mg daily." | ( Appelhof, BC; Brouwer, JP; Fliers, E; Hoogendijk, WJ; Huyser, J; Schene, AH; Tijssen, JG; van Dyck, R; Wiersinga, WM, 2004) |
| "Up to a third of elderly patients with major depressive disorder are treatment resistant, yet little objective evidence is available to guide the clinician in managing these patients." | ( Basinski, J; Begley, A; Dew, MA; Farhi, P; Mulsant, BH; Reynolds, CF; Whyte, EM, 2004) |
| "Fifty-three elderly subjects with major depressive disorder according to DSM-IV criteria who failed treatment with paroxetine plus interpersonal psychotherapy received 1 to 3 trials of augmentation with bupropion sustained release, nortriptyline, or lithium." | ( Basinski, J; Begley, A; Dew, MA; Farhi, P; Mulsant, BH; Reynolds, CF; Whyte, EM, 2004) |
| "Subjects were 24 patients with major depressive disorders who presented to the outpatient clinic of the Department of Psychiatry at the National Defense Medical College prior to any treatment for the current episode." | ( Kobayashi, N; Nomura, S; Sawamura, T; Yoshida, T; Yoshino, A, 2004) |
| "A 66-year-old woman with major depressive disorder had been treated with brotizolam 0." | ( Arima, Y; Kubo, C; Ohtani, H; Sawada, Y; Tsujimoto, M, 2005) |
| "Nine patients diagnosed as major depressive disorder (MDD), with erectile dysfunction associated with the administration of SSRIs, completed a 2-week trial of loratadine in the dose of 10 mg/day." | ( Aukst-Margetić, B; Margetić, B, 2005) |
| "Rapid improvement in quality of life in major depressive disorder was showed in patients treated with combination of late partial sleep deprivation and sertraline." | ( Caliyurt, O; Guducu, F, 2005) |
| "Fifteen patients with major depressive disorder (diagnosed with a site-generated form described in the text) and an incomplete response or no response to > or = 8 weeks of antidepressant (selective serotonin reuptake inhibitor, venlafaxine, or bupropion) monotherapy were treated with aripiprazole augmentation in an 8-week, open-label study." | ( Nemeroff, CB; Simon, JS, 2005) |
| "Adolescents with major depressive disorder (MDD), their families and clinicians experience significant challenges when weighing the potential risks versus benefits of available choices in the treatment of MDD." | ( Kratochvil, CJ; March, JS; Pathak, S; Rogers, GM; Silva, S; Vitiello, B; Weller, EB, 2005) |
| "Thirty-seven patients with major depressive disorder were randomly allocated into 3 treatment groups." | ( Abay, E; Caliyurt, O; Güdücü, F; Tuğlu, C; Vardar, E, 2005) |
| "Efforts to treat major depressive disorder in alcoholics with antidepressants have yielded mixed results." | ( Anthenelli, R; Brower, KJ; Cornelius, J; Hasin, D; Keller, M; Kranzler, HR; Martin, PR; Mason, BJ; Moak, D; Mueller, T; O'Malley, S; Pettinati, HM, 2006) |
| "Patients with major depressive disorder (MDD) treated with olanzapine in combination with fluoxetine (OFC) demonstrate robust improvement in their depressive symptoms." | ( Andersen, SW; Clemow, DB; Corya, SA, 2005) |
| "Patients with major depressive disorder or dysthymic disorder achieved similar clinical improvement in both treatment groups (mean MADRS ratings decrease in major depressive disorder from baseline to 6 months of 18." | ( Caramés, E; Gabarron, E; Garcia-Bayo, I; Haro, JM; Peñarrubia-Maria, MT; Pinto-Meza, A; Serrano-Blanco, A; Soler-Vila, M, 2006) |
| "Many patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitors have residual symptoms (eg, persistent fatigue, excessive sleepiness) despite an overall antidepressant response." | ( Arora, S; DeBattista, C; Fava, M; Hughes, RJ; Thase, ME, 2006) |
| "Patients (6-17 years old) with major depressive disorder were randomized to receive 8 weeks of double-blind flexibly dosed treatment with escitalopram (10-20 mg/day; n = 131) or placebo (n = 133)." | ( Findling, RL; Jonas, J; Saikali, K; Ventura, D; Wagner, KD, 2006) |
| "Outpatients (n = 232) with major depressive disorder were randomly assigned to 8 weeks of treatment with either "standard" (n = 119; mean dose = 148 mg/d) or "higher" (n = 113; mean dose = 309 mg/d) dosage therapies." | ( Khan, A; Shelton, RC; Thase, ME, 2006) |
| "Eighteen patients with major depressive disorder (DSM-IV criteria) were treated for 20 weeks with quetiapine (mean dose 315+/-109 mg/day)." | ( Jakovljević, M; Mihaljević-Peles, A; Mück-Seler, D; Pivac, N; Sagud, M, 2006) |
| "Adult outpatients with nonpsychotic major depressive disorder who had not achieved remission or had withdrawn from treatment because of intolerance in three previous prospective medication trials were randomly assigned to receive open-label treatment with either tranylcypromine (N=58) or extended-release venlafaxine plus mirtazapine (N=51)." | ( Biggs, MM; Davis, L; Fava, M; Luther, JF; McGrath, PJ; Niederehe, G; Nierenberg, AA; Rush, AJ; Shores-Wilson, K; Stewart, JW; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR, 2006) |
| "Five hundred seventy persons with major depressive disorder were treated with fluoxetine for 12 weeks and their pattern of response was determined." | ( Alpert, JE; Chen, Y; Cheng, J; Fava, M; McGrath, PJ; Nierenberg, AA; Petkova, E; Quitkin, FM; Stewart, JW, 2006) |
| "Recurrent major depressive disorder (MDD) is a common and disabling illness, but few studies have addressed long-term antidepressant treatment of recurrent MDD (ie, beyond 1 year of maintenance therapy) or compared the efficacy and safety of different antidepressant classes in this population." | ( Kornstein, SG, 2006) |
| "Patients (N = 27) with major depressive disorder received a standard antidepressant treatment (Venlafaxine, Escitalopram) plus flexible dose of quetiapine." | ( Baune, BT; Caliskan, S; Todder, D, 2007) |
| "Eighty inpatients with an episode of major depressive disorder (DSM-IV criteria) were treated in a double-blind, randomized protocol with either amitriptyline or paroxetine over a period of 5 weeks." | ( Deuschle, M; Gilles, M; Heuser, I; Lederbogen, F; Weber-Hamann, B, 2006) |
| "Subjects with DSM-IV major depressive disorder were randomly assigned to 8 weeks of double-blind treatment with sertraline (N = 82) or venlafaxine XR (N = 78)." | ( Dunner, DL; Haman, KL; Hirschfeld, RM; Kiev, A; Lydiard, RB; Rapaport, MH; Shelton, RC; Smith, WT; Zajecka, JM, 2006) |
"Patients with recurrent DSM-IV-defined major depressive disorder (>or= 2 previous episodes; baseline Montgomery-Asberg Depression Rating Scale [MADRS] score >or= 22) who had responded (MADRS score | ( Bose, A; Gandhi, C; Kornstein, SG; Li, D; Saikali, KG, 2006) | |
| "Because major depressive disorder (MDD) is often chronic and recurrent, even pediatric patients who are treated successfully during an acute episode may need longer-term treatment." | ( Emslie, GJ; Kunz, NR; Yeung, PP, 2007) |
| "We present a case of severe, recurrent major depressive disorder that demonstrated marked improvement within 8 hours of receiving a preoperative dose of ketamine and 1 treatment of electroconvulsive therapy with bitemporal electrode placement." | ( Goforth, HW; Holsinger, T, 2007) |
| "Psychiatrists treated major depressive disorder in advanced cancer patients on the basis of the algorithm." | ( Akechi, T; Akizuki, N; Ito, T; Nakano, T; Okamura, M; Shimizu, K; Uchitomi, Y, 2008) |
| "Patients with major depressive disorder (confirmed by the Structured Clinical Interview for DSM-IV) were treated with sertraline at doses up to 200 mg/day in this study, conducted from June 18, 2003, to January 28, 2005." | ( Adler, LA; Amsterdam, JD; Dunner, DL; Kelsey, DK; Michelson, D; Nierenberg, AA; Reimherr, FW; Schatzberg, AF; Williams, DW, 2007) |
| "Treatment of major depressive disorder typically entails implementing treatments in a stepwise fashion until a satisfactory outcome is achieved." | ( Biggs, MM; Fava, M; Friedman, ES; Lavori, PW; McGrath, PJ; Miyahara, S; Niederehe, G; Rush, AJ; Sackeim, HA; Shores-Wilson, K; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR, 2007) |
| "Current antidepressants used in major depressive disorder (MDD) are still not efficacious enough for many patients due to high levels of treatment resistance and bothersome side-effects." | ( Kasper, S; Olié, JP, 2007) |
| "Patients Individuals with nonpsychotic major depressive disorder for whom DNA was available and who did not report suicidal ideation at study entry were subsequently treated with citalopram hydrobromide for up to 12 weeks." | ( Fagerness, J; Fava, M; Perlis, RH; Purcell, S; Rush, AJ; Smoller, JW; Trivedi, MH, 2007) |
| "Hypoperfusion in major depressive disorder largely normalizes after a response to pharmacotherapy." | ( Bonne, O; Chisin, R; Freedman, N; Kohn, Y; Krausz, Y; Lerer, B; Lester, H, 2007) |
| "Up to a third of elderly patients with major depressive disorder do not respond to a first course of treatment with an antidepressant." | ( Heeren, TJ; Kok, RM; Nolen, WA; Vink, D, 2007) |
| "Treatment for major depressive disorder does not achieve remission in about 50% of patients following 2 treatment trials." | ( Rush, AJ, 2007) |
| "Outpatients with a primary diagnosis of major depressive disorder were treated with fixed once-daily doses of desvenlafaxine 200 or 400 mg for 8 weeks." | ( Germain, JM; Padmanabhan, SK; Pitrosky, B; Septien-Velez, L; Tourian, KA, 2007) |
| "Thirty youth with major depressive disorder (MDD) and 23 control youth reported on caffeine use, sleep, and affect in their natural environment using ecological momentary assessment at baseline and over 8 weeks, while MDD youth received treatment." | ( Axelson, DA; Birmaher, B; Dahl, RE; Forbes, EE; Ryan, ND; Semel, M; Silk, JS; Whalen, DJ, 2008) |
| "274 outpatient adults with major depressive disorder that was suboptimally responsive to antidepressant therapy." | ( Canuso, CM; Gharabawi-Garibaldi, GM; Kosik-Gonzalez, C; Kujawa, MJ; Mahmoud, RA; Pandina, GJ; Turkoz, I, 2007) |
| "Eighty-one Japanese patients with major depressive disorder were treated with milnacipran for 6 weeks." | ( Higuchi, H; Inoue, K; Itoh, K; Kamata, M; Ozaki, N; Sato, K; Suzuki, T; Takahashi, H; Yoshida, K, 2008) |
| "Experience of pain in major depressive disorder (MDD) can complicate diagnosis and impair treatment outcomes." | ( Brecht, S; Courtecuisse, C; Croenlein, J; Debieuvre, C; Demyttenaere, K; Desaiah, D; Petit, C; Raskin, J, 2007) |
| "Patients with major depressive disorder (MDD) experience sleep disturbances that may be worsened by some antidepressant drugs early in treatment." | ( Alvarez, E; Guilleminault, C; Lemoine, P, 2007) |
| "Forty-five inpatients with a chronic Major Depressive Disorder were randomized to 5 weeks of either Interpersonal Psychotherapy (IPT) modified for an inpatient setting (15 individual and 8 group sessions) plus pharmacotherapy or to medication plus Clinical Management (CM)." | ( Berger, M; Dykierek, P; Härter, M; Kech, S; Schneider, D; Schramm, E; van Calker, D; Zobel, I, 2008) |
| "Whether the acute outcomes of major depressive disorder (MDD) treated in primary (PC) or specialty care (SC) settings are different is unknown." | ( Balasubramani, GK; Fava, M; Gaynes, BN; Klinkman, M; McGrath, PJ; Nierenberg, AA; Rush, AJ; Thase, ME; Trivedi, MH; Wisniewski, SR; Yates, WR, 2008) |
| "Patients with major depressive disorder (DSM-IV) who showed favorable treatment response to venlafaxine (mean +/- SD dose = 116." | ( Chen, MC; Lane, HY; Lin, CH; Lin, CY; Lin, KS, 2008) |
| "Adult outpatients with DSM-IV major depressive disorder, a Hamilton Rating Scale for Depression (HAM-D(17)) total score of >or= 15, and a Clinical Global Impressions-Severity of Illness score of >or= 3 despite at least 6 weeks of SSRI treatment were randomly assigned to either abrupt discontinuation of SSRI immediately followed by initiation of duloxetine (direct switch [DS]; N = 183) or tapered discontinuation of SSRI over 2 weeks and simultaneous administration of duloxetine (start-taper switch [STS]; N = 185)." | ( Corruble, E; Desaiah, D; Fava, M; Perahia, DG; Quail, D, 2008) |
| "Although major depressive disorder (MDD) is a treatable disease, the remission rates associated with antidepressant monotherapy are still far from optimal." | ( Morris, DW; Rush, AJ; Trivedi, MH, 2008) |
| "In the group with major depressive disorder, treatment with antidepressants showed an increase from 15% to 30%." | ( Beekman, AT; Comijs, HC; Deeg, DJ; Sonnenberg, CM; van Tilburg, W, 2008) |
| "Insomnia impacts the course of major depressive disorder (MDD), hinders response to treatment, and increases risk for depressive relapse." | ( Edinger, JD; Gress, JL; Kalista, T; Kuo, TF; Manber, R; San Pedro-Salcedo, MG, 2008) |
| "This is a report of a woman with a major depressive disorder who complained of diffuse scalp hair loss during treatment with sertraline." | ( Ghanizadeh, A, 2008) |
| "Perinatal Major Depressive Disorder (MDD) is common and poses particular treatment dilemmas." | ( Freeman, MP, 2009) |
| "The subjects were 313 patients with major depressive disorder and 17-item Hamilton Rating Scale for Depression (HAM-D-17) scores between 14 and 25 who were treated for 6 months with either pharmacotherapy, short-term psychodynamic supportive psychotherapy or combined therapy." | ( Dekker, J; Peen, J; Schoevers, RA; van Aalst, G; Van, HL, 2008) |
| "A total of 114 patients with major depressive disorder were enrolled in an 8-week treatment study." | ( Fava, M; Garakani, A; Hirschowitz, J; Marcus, S; Martinez, JM; Rickels, K; Weaver, J, 2008) |
| "Most patients with major depressive disorder (MDD) experience a period of lengthy trial and error when trying to find optimal antidepressant treatment; identifying biomarkers that could predict response to antidepressant treatment would be of enormous benefit." | ( Colon-Rosario, V; Coppola, R; Cornwell, BR; Grillon, C; Manji, HK; Salvadore, G; Zarate, CA, 2009) |
| "All mothers had been diagnosed with major depressive disorder and were treated initially with citalopram; 33% of mothers experienced remission of depressive symptoms." | ( Alpert, JE; Cerda, G; Fava, M; Foster, CE; Garber, J; Hughes, CW; King, CA; Kornstein, SG; Malloy, E; Pilowsky, DJ; Rush, AJ; Talati, A; Trivedi, MH; Webster, MC; Weissman, MM; Wickramaratne, PJ; Wisniewski, SR, 2008) |
| "Participants with major depressive disorder (N = 2875) at primary and specialty care sites who received the first step treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression study were included." | ( Fava, M; Khan, AY; McGrath, PJ; Miyahara, S; Morris, DW; Nierenberg, AA; Rush, AJ; Stewart, JW; Trivedi, MH; Wisniewski, SR, 2008) |
| "Adolescents with major depressive disorder (N=439) were randomly assigned to receive an initial 12 weeks of treatment with fluoxetine, cognitive-behavioral therapy (CBT), combination treatment with fluoxetine and CBT, or clinical management with placebo; those assigned to placebo received open active treatment as clinically indicated after 12 weeks of placebo." | ( Curry, JF; Emslie, GJ; Hughes, JL; Kennard, BD; Kratochvil, CJ; March, JS; Mayes, TL; Reinecke, MA; Rohde, P; Silva, SG; Vitiello, B, 2009) |
| "Twelve patients with major depressive disorder and an incomplete or no response to different kinds of antidepressants (selective serotonin reuptake inhibitor, milnacipran, or sulpride) monotherapy or polytherapy for 8 weeks or more were treated with perospirone augmentation in an eight-week, open-label study." | ( Kaneko, S; Nakagami, T; Saito, M; Sato, Y; Yasui-Furukori, N, 2009) |
| "Untreated major depressive disorder (MDD) is a major risk factor for suicide, but some data suggest antidepressants may be associated with increased suicidal ideation (SI) in some depressed patients." | ( Fava, M; Lebowitz, B; Luther, J; Moutier, C; Rush, AJ; Stewart, JW; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR; Zisook, S, 2009) |
| "Existing treatments for major depressive disorder (MDD) usually take weeks to months to achieve their antidepressant effects, and a significant number of patients do not have adequate improvement even after months of treatment." | ( Diazgranados, N; Machado-Vieira, R; Salvadore, G; Zarate, CA, 2009) |
| "Desvenlafaxine in the treatment of major depressive disorder exhibited a safety and tolerability profile generally consistent with the serotonin-norepinephrine reuptake inhibitor class." | ( Clayton, AH; Guico-Pabia, C; Kornstein, SG; Rosas, G; Tourian, KA, 2009) |
| "Many patients with major depressive disorder (MDD) who experience full symptomatic remission after antidepressant treatment still have residual depressive symptoms." | ( Fava, M; Husain, MM; Miyahara, S; Nierenberg, AA; Rush, AJ; Trivedi, MH; Warden, D; Wisniewski, SR, 2010) |
| "276 patients with major depressive disorder (MDD) were treated with sertraline (150-200 mg daily) for 8 weeks." | ( Adler, LA; Amsterdam, JD; Dunner, DL; Michelson, D; Nierenberg, AA; Reimherr, FW; Schatzberg, AF; Williams, D, 2009) |
| "Outpatients with nonpsychotic major depressive disorder treated for up to 14 weeks with citalopram in the first step of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study were divided by household incomes of <$20,000, $20,000-<$40,000, and >or=$40,000." | ( Balasubramani, GK; Lesser, IM; Nierenberg, AA; Rush, AJ; Shores-Wilson, K; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR, 2009) |
| "Patients who met the criteria for major depressive disorder were treated for 6 weeks with fluoxetine, paroxetine or citalopram." | ( Huhtala, H; Illi, A; Kampman, O; Lehtimäki, T; Leinonen, E; Mononen, N; Poutanen, O; Setälä-Soikkeli, E; Viikki, M, 2009) |
| "Individuals with Major Depressive Disorder (MDD) vary regarding the rate, magnitude and stability of symptom changes during antidepressant treatment." | ( Cook, IA; Hunter, AM; Leuchter, AF; Muthén, BO, 2010) |
| "A total of 796 adult patients with major depressive disorder who were treated with a flexible dosage of escitalopram or nortriptyline in Genome-based Therapeutic Drugs for Depression (GENDEP) were included in the sample and provided data on suicidal ideation." | ( Aitchison, KJ; Bonvicini, C; Craig, I; Farmer, AE; Gray, J; Gupta, B; Hauser, J; Henigsberg, N; Huezo-Diaz, P; Jorgensen, L; Kalember, P; Kapelski, P; Lewis, CM; Maier, W; Marusic, A; McGuffin, P; Mors, O; Perroud, N; Petrovic, A; Placentino, A; Rietschel, M; Schulze, TG; Smith, R; Souery, D; Uher, R; Zobel, A, 2009) |
| "Patients with DSM-IV-TR major depressive disorder who responded to an 8- or 10-week course of agomelatine 25- or 50-mg daily treatment were randomly assigned to receive continuation treatment with agomelatine (n=165) or placebo (n=174) during a 24-week, randomized, double-blind treatment period." | ( Emsley, R; Goodwin, GM; Rembry, S; Rouillon, F, 2009) |
| "95 outpatients with major depressive disorder were treated for 6 weeks with EA, fluoxetine or placebo." | ( Halbreich, U; Han, C; Leonard, BE; Luo, H; Song, C, 2009) |
| "Anxious depression, defined as major depressive disorder (MDD) accompanied by high levels of anxiety, seems to be both common and difficult to treat, with antidepressant monotherapy often yielding modest results." | ( Ameral, VE; Baer, L; Brintz, C; Clain, A; Fava, M; Glaudin, V; Londborg, PD; Painter, JR; Papakostas, GI; Smith, WT, 2010) |
| "Patients with major depressive disorder were randomized to once-daily treatment with bupropion XR 150 mg (n = 204), the extended-release formulation of venlafaxine (venlafaxine XR) 75 mg (n = 198) or placebo (n = 189) during weeks 1 to 4, with the option to double the dose at week 5 if response was inadequate." | ( Evoniuk, G; Gee, MD; Hewett, K; Krishen, A; Le Clus, A; Modell, JG; Wunderlich, HP, 2010) |
| "More than half of older adults with major depressive disorder require extended treatment because of incomplete response during acute treatment." | ( Andreescu, C; Dew, MA; Greenlee, A; Houck, P; Karp, JF; Reynolds, CF, 2010) |
| "Patients Individuals with nonpsychotic major depressive disorder for whom DNA was available who were subsequently treated with citalopram hydrobromide for 4 to 12 weeks." | ( Binder, EB; Bradley, B; Deveau, TC; Fava, M; Liu, W; Nemeroff, CB; Owens, MJ; Ressler, KJ; Rush, AJ; Trivedi, MH, 2010) |
| "Seventy-two major depressive disorder (MDD) subjects were treated with fluoxetine 20 mg (n = 13), venlafaxine 150 mg (n = 24), or placebo (n = 35) under double-blind conditions." | ( Abrams, M; Cook, IA; Hunter, AM; Leuchter, AF, 2010) |
| "35 patients with DSM IV-defined major depressive disorder of mild or moderate severity were randomized to receive either short-term psychodynamic psychotherapy or fluoxetine treatment for 16 weeks." | ( Hietala, J; Kajander, J; Karlsson, H; Kronström, K; Markkula, J; Rasi-Hakala, H; Salminen, JK; Vahlberg, T, 2011) |
| "Adult outpatients with recurrent major depressive disorder (MDD) and response or remission following 6-month continuation treatment with venlafaxine extended release (ER) were randomized to receive venlafaxine ER or placebo for 1 year." | ( Dunner, DL; Friedman, ES; Gelenberg, A; Keller, MB; Kocsis, JH; Kornstein, SG; Rothschild, AJ; Shelton, RC; Thase, ME; Trivedi, MH; Zajecka, JM, 2010) |
| "Seventy-five elderly patients with major depressive disorder in remission underwent assessment of insight using the Mood Disorders Insight Scale (MDIS), including awareness, attribution, and need for treatment." | ( Chang, HC; Chen, CS; Ko, CH; Kuo, YT; Li, CW; Lin, HF; Liu, GC; Yeh, YC; Yen, CF, 2010) |
| "Twenty-five patients diagnosed with major depressive disorder were assessed twice, pretreatment and at 8-wk follow-up, on a variety of QEEG and neuropsychological tasks." | ( Arns, M; Barnett, KJ; Cooper, NJ; Gordon, E; Spronk, D, 2011) |
| "For many patients suffering from major depressive disorder, available treatments are unsatisfactory due to long delays before the onset of effects, low response rates, poor tolerability, and high recurrence rates." | ( Gorwood, P, 2010) |
| "Patients with DSM-IV-TR-diagnosed major depressive disorder with an inadequate response to 8 weeks of prospective antidepressant treatment were randomly assigned to adjunctive placebo or adjunctive aripiprazole (2-20 mg/d) treatment for 6 weeks." | ( Berman, RM; Carlson, BX; Eudicone, JM; Khan, A; Pikalov, A; Tran, QV; Trivedi, MH; Weisler, RH; Yang, H, 2011) |
| "Twenty-four untreated patients with major depressive disorder (according to Structured Clinical Interview for DSM-IV) were enrolled in a prospective, randomized, 4-week trial with mirtazapine and venlafaxine." | ( Bokde, AL; Brückmann, H; Frodl, T; Hampel, H; Koutsouleris, N; Linn, J; Meisenzahl, E; Möller, HJ; Scheuerecker, J; Schoepf, V; Wiesmann, M, 2011) |
| "Studies in major depressive disorder (MDD) with both escitalopram and citalopram treatment arms were identified." | ( Hansen, T; Kasper, S; Montgomery, S, 2011) |
| "The treatment of major depressive disorder requires prolonged pharmacotherapy with antidepressants in order to resolve the current episode and reduce the risk for recurrence of depressive symptoms." | ( Navarro, V, 2010) |
| "Although the goal of treatment for major depressive disorder is full remission, for most patients, remission is the exception rather than the rule." | ( Fava, M; Mischoulon, D, 2010) |
| "Many patients with major depressive disorder (MDD) who achieve full remission after antidepressant treatment still have residual depressive symptoms." | ( Baer, L; Clain, A; Iovieno, N; Nierenberg, AA; van Nieuwenhuizen, A, 2011) |
| "Postmenopausal women with major depressive disorder who did not respond to acute, double-blind treatment with escitalopram or desvenlafaxine achieved modest, continued improvement with long-term, open-label desvenlafaxine therapy." | ( Clayton, A; Focht, K; Guico-Pabia, CJ; Jiang, Q; Kane, CP; Kornstein, SG; Ninan, PT; Soares, CN; Thase, ME, 2011) |
| "However, in patients with major depressive disorder (MDD), a greater incidence of suicidal behavior occurred in paroxetine-treated patients than in placebo-treated patients (n/n = 11/3,455 [0." | ( Carpenter, DJ; Davies, JT; Fong, R; Kraus, JE; Moore, C; Thase, ME, 2011) |
| "In patients with major depressive disorders treated with citalopram, 80% 5-HTT occupancy was considered to be necessary for maximal therapeutic effects, which requires citalopram serum concentrations of at least 50 ng/mL." | ( Boland, K; Dragicevic, A; Fric, M; Hiemke, C; Laux, G; Müller, MJ; Ostad Haji, E; Rao, ML; Tadić, A; Wagner, S, 2011) |
| "In treatment trials for major depressive disorder (MDD), early symptom improvement is predictive of eventual clinical response." | ( Cook, IA; Hunter, AM; Korb, AS; Leuchter, AF, 2011) |
| "Approximately 50% of patients with major depressive disorder (MDD) do not respond after adequate first-line treatment with a selective serotonin reuptake inhibitor (SSRI)." | ( Barak, Y; Baruch, Y; Swartz, M, 2011) |
| "Patients with major depressive disorder (MDD) show deficits in processing of facial emotions that persist beyond recovery and cessation of treatment." | ( Bhagwagar, Z; Blumberg, HP; Kerestes, R; Ladouceur, CD; Maloney, K; Meda, S; Nathan, PJ; Pearlson, GD; Phillips, ML; Ruf, B; Saricicek, A, 2012) |
| "The goal of treating major depressive disorder is to achieve remission." | ( Chen, CC; Juo, SH; Lane, HY; Lin, CH; Yen, CF, 2011) |
| "Treatment guidelines for major depressive disorder (MDD) recommend a continuous use of antidepressants for several weeks, while recent meta-analyses indicate that antidepressant efficacy starts to appear within 2 weeks and early treatment nonresponse is a predictor of subsequent nonresponse." | ( Abe, T; Hirano, J; Kashima, H; Mimura, M; Nakajima, S; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K; Yagihashi, T, 2011) |
| "Helping patients with major depressive disorder achieve symptom-free remission with antidepressant therapy remains challenging." | ( Fava, M; Shelton, RC; Zajecka, JM, 2011) |
| "Three hundred forty adults with major depressive disorder (according to the Structured Clinical Interview for DSM-IV) and baseline scores of ≥ 20 on the 17-item Hamilton Depression Rating Scale (HDRS-17) were randomized to Hypericum perforatum 900-1,500 mg/d, sertraline 50-100 mg/d, or placebo and were asked to guess their assigned treatment after 8 weeks." | ( Baer, L; Chen, JA; Clain, AJ; Fava, M; Mischoulon, D; Papakostas, GI; Youn, SJ, 2011) |
| "In this study, 120 patients with major depressive disorders were treated with 10-40 mg/day of paroxetine for 6 weeks, and a total of 89 patients completed the protocol." | ( Inoue, Y; Kaneda, A; Kaneko, S; Nakagami, T; Otani, K; Suzuki, A; Yasui-Furukori, N, 2011) |
| "Apathy in the context of treated major depressive disorder (MDD) is a common but understudied symptom." | ( George, T; Granger, RE; Hussain, N; Marangell, LB; Raskin, J; Zhao, GW, 2012) |
| "Eighty-nine adults with Major Depressive Disorder (MDD), characterized as antidepressant-experienced or antidepressant-naive, received one week of single-blind placebo treatment prior to eight weeks of randomized treatment with medication (fluoxetine or venlafaxine; n = 47) or placebo (n = 42) in one of three similar placebo-controlled trials." | ( Cook, IA; Hunter, AM; Leuchter, AF, 2012) |
| "Unrecognized and untreated major depressive disorder and sub-syndromal symptoms were frequent in patients of MI." | ( Agarwal, M; Dalal, PK; Saran, RK; Sinh, PK; Trivedi, JK, 2011) |
| "Affective disorders, including major depressive disorder (MDD), are among the most severely disabling mental disorders, and in many cases are associated with poor treatment outcomes." | ( Berrocoso, E; Elorza, J; Mico, JA; Perez-Caballero, L; Torres-Sanchez, S, 2012) |
| "In self-identified white patients with major depressive disorder (N=126) treated with open-label duloxetine (60-120 mg/d), a significant association of (P=0." | ( Aris, V; Chen, P; Fijal, B; Heinloth, AN; Houston, JP; Martinez, J; Zou, W, 2012) |
| "Subjects with major depressive disorder or bipolar disorder referred for ECT treatment of a major depressive episode were randomized to receive thiopental alone or thiopental plus ketamine (0." | ( Abdallah, CG; Fasula, M; Kelmendi, B; Ostroff, R; Sanacora, G, 2012) |
| "The symptoms of major depressive disorder (MDD) include sexual dysfunction, but antidepressant pharmacotherapies are also associated with treatment-emergent sexual dysfunction." | ( Clayton, AH; Fayyad, R; Focht, K; Musgnung, J; Reddy, S, 2013) |
| "75 adult patients with DSM-IV major depressive disorder, recruited from psychiatric wards, psychiatric specialist practices, or general medical practices between September 2005 and August 2008, were randomly assigned to a 9-week chronotherapeutic intervention using wake therapy, bright light therapy, and sleep time stabilization (n = 37) or a 9-week intervention using daily exercise (n = 38)." | ( Bech, P; Lindberg, L; Lund, V; Lunde, M; Martiny, K; Refsgaard, E; Sørensen, L; Thougaard, B, 2012) |
| "Patients with major depressive disorder who responded to an 8/10-week course of agomelatine 25-50 mg treatment were randomly assigned to receive continuation treatment with agomelatine or placebo during a 24-week, randomized, double-blind treatment period with an optional 18- or 20-week double-blind extension period." | ( Boyer, P; de Bodinat, C; Emsley, R; Goodwin, GM; Rouillon, F, 2013) |
| "Twenty-six treatment-resistant major depressive disorder patients participated in a double blind, placebo-controlled, 6-wk parallel group trial with a gradually titrated high dose (1000 mg/d) of DCS added to their antidepressant medication." | ( Bloch, B; Edelman, S; Gelfin, G; Heresco-Levy, U; Javitt, DC; Kremer, I; Levin, R, 2013) |
| "To study ziprasidone monotherapy for major depressive disorder, defined according to the DSM-IV." | ( Abrams, J; Bari, MA; Fava, M; Hails, KA; Ishak, WW; Kinrys, G; Lipkin, SH; Meisner, A; Mischoulon, D; Okasha, MS; Papakostas, GI; Rapaport, MH; Schoenfeld, DA; Shelton, RC; Vitolo, OV; Ward, SG; Winokur, A; Zajecka, JM, 2012) |
| "The precise neural substrates of major depressive disorder (MDD) remain elusive, and FDA-approved antidepressants fail at least one-third of treatment-seeking patients." | ( Collins, KA; Schiller, D, 2013) |
| "Smaller hippocampal volumes in major depressive disorder (MDD) have been linked with earlier onset, previous recurrences and treatment refractoriness." | ( Álvarez, E; de Diego-Adeliño, J; Gómez-Ansón, B; López-Moruelo, O; Pérez, V; Pérez-Egea, R; Portella, MJ; Puigdemont, D; Serra-Blasco, M; Vives, Y, 2013) |
| "Responses to venlafaxine treatment in major depressive disorder were stratified by COMT genotypes (Val158Met, rs4680) in a randomized, double-blind, placebo-controlled clinical trial." | ( Hopkins, SC; Koblan, KS; Reasner, DS, 2013) |
| "negative stimuli in patients with major depressive disorder (MDD) under antidepressant treatment." | ( Drevets, WC; Fromm, SJ; Furey, ML; Öhman, A; Victor, TA, 2013) |
| "Patients with treatment-resistant major depressive disorder (MDD) remain a common clinical challenge." | ( Bauer, M; Dell'osso, L; Dencker Vansvik, E; Jørgensen, L; Kasper, S; Köhler, J; Montgomery, SA; Pitchot, W, 2013) |
| "Approximately 50% of patients with major depressive disorder (MDD) do not respond optimally to antidepressant treatments." | ( Etkin, A; Gordon, E; Grieve, SM; Harris, A; Korgaonkar, MS; Koslow, SH; Nemeroff, CB; Schatzberg, AF; Williams, LM; Wisniewski, S, 2013) |
| "Patients with chronic or recurrent major depressive disorder (MDD) have faced a dearth of treatment options." | ( Cho, SJ; Choi, JH; Hahn, SW; Han, C; Jeon, HJ; Jon, DI; Jun, TY; Kim, SG; Kim, W; Kwak, KP; Lee, BC; Pae, CU; Park, EJ; Seo, HJ, 2013) |
| "Multiple treatments for patients with major depressive disorder (MDD) have demonstrated efficacy, but up to one-third of individuals with MDD do not achieve symptomatic remission despite various interventions." | ( Cusin, C; Fava, M; Iosifescu, DV; Iovieno, N; Nierenberg, AA; Perlis, RH; Rush, AJ, 2013) |
| "Patients with major depressive disorder (MDD) accompanied by physical symptoms may be less responsive to antidepressant treatment." | ( Anghelescu, I; Luborzewski, A; Quante, A; Regen, F; Roepke, S; Schindler, F; Severus, E; Urbanek, C; Volkmer, K, 2013) |
| "Patients with major depressive disorder often experience relapse after responding to treatment; therefore, maintenance therapy with antidepressants is recommended for maintaining response or remission." | ( Alam, MY; Chen, Y; Jacobsen, PL; Mahableshwarkar, AR; Serenko, M, 2014) |
| "Twenty-one patients with major depressive disorder and without other Axis I or Axis II diagnoses were scanned before treatment and 2 and 6 months into treatment at the university's functional magnetic resonance imaging facility." | ( Davidson, RJ; Heller, AS; Johnstone, T; Kalin, NH; Kolden, GG; Peterson, MJ, 2013) |
| "Adult outpatients with major depressive disorder and partial response or nonresponse to their current antidepressant (as indicated by a 17-item Hamilton Depression Rating Scale score of ≥ 16 at baseline) were randomized (from July 2006-December 2011) to add memantine (flexible dose 5-20 mg/d, with all memantine group participants reaching the dose of 20 mg/d) (n = 15) or placebo (n = 16) to their existing treatment for 8 weeks." | ( Deligiannidis, KM; Landolin, CS; Patel, JK; Rothschild, AJ; Smith, EG; Ulbricht, CM, 2013) |
| "Studies on major depressive disorders (MDD) pathophysiology show decreased blood levels of brain-derived neurotrophic factor (BDNF) that increase after antidepressant treatment." | ( Bechon, E; Cappellin, F; Fania, S; Mengozzi, G; Munno, D; Saroldi, M; Sterpone, S; Zullo, G, 2013) |
| "Treatment approaches for major depressive disorder (MDD) result in approximately one third of patients achieving remission after a first treatment." | ( Craighead, WE; Dunlop, BW; Holtzheimer, PE; Kelley, ME; Mayberg, HS; McGrath, CL, 2014) |
| "Twenty-five patients with major depressive disorder underwent standardized treatment with duloxetine." | ( Beck, J; Bischof, R; Brand, S; Delini-Stula, A; Eckert, A; Hemmeter, U; Holsboer-Trachsler, E; Mikoteit, T, 2014) |
| "Several studies of patients with major depressive disorder (MDD) have confirmed the superior efficacy and safety of agomelatine in comparison with established treatments, such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs)." | ( Hsu, CC; Hu, GC; Huang, KL; Lee, WY; Lu, CH; Lu, WC; Wang, YY, 2014) |
| "60 inpatients suffering from major depressive disorder (MDD) according to DSM-IV were randomized for a 5 week treatment with Yoga or not (control group) and with either QXR (300 mg/day) or ESC (10 mg/day)." | ( Baghai, TC; Born, C; Bühner, M; Konopka, K; Lieb, M; Nothdurfter, C; Rupprecht, R; Sarubin, N; Schüle, C; Uhr, M; Zimmermannc, R, 2014) |
| "47 patients with Major Depressive Disorder, treated with V 75 - 300 mg/day, underwent CYP2D6 genotyping using the INFINITI-CYP2D6 assay." | ( Bellomo, G; Dalò, V; Gramaglia, C; Meola, S; Pollarolo, P; Prosperini, P; Ressico, F; Rolla, R; Torre, E; Vidali, M; Zeppegno, P, 2014) |
| "Older subjects with non-psychotic major depressive disorder were treated with citalopram in an 8-week open-label study." | ( Johns, B; Lim, KO; Shiroma, PR; Thuras, P, 2014) |
| "Adult outpatients with major depressive disorder who completed the 24 weeks of open-label treatment with desvenlafaxine 50 mg/d were randomly assigned to no discontinuation (desvenlafaxine 50 mg/d), taper (desvenlafaxine 25 mg/d), or abrupt discontinuation (placebo) groups for the double-blind (DB) taper phase." | ( Buckley, G; Khan, A; Messig, M; Musgnung, J; Ninan, PT; Ramey, T, 2014) |
| "Patients with major depressive disorder (MDD) who failed to satisfactorily respond to ≥ 2 different antidepressants for ≥ 6 weeks within the current MDD episode were acutely treated for 6-8 weeks, followed by stabilization (12 weeks) on OFC." | ( Brunner, E; Landry, J; Osuntokun, O; Thase, ME; Tohen, M, 2014) |
| "For the treatment of major depressive disorder, our results show that a dose of 5 mg/day vortioxetine was more effective, but more easily induced nausea, compared to placebo." | ( Chen, Y; Fu, J, 2015) |
| "Patients with major depressive disorder (MDD) frequently also have alcohol use disorder (AUD) and they are more likely to experience symptomatic recurrence and resist treatment." | ( Hashimoto, E; Ishikawa, H; Saito, T; Tayama, M; Yamamoto, M, 2015) |
| "59 moderate Alzheimer patients with major depressive disorder were randomly divided into 3 groups (sertraline, venlafaxine and desipramine), treated for 12 weeks (150 mg maximum dose) and assessed by the Hamilton Depression Test (HRSD), the Mini Mental State Examination (MMSE) and the Barthel index at the week 0 and the 2(nd), 4(th), 8(th), 12(th) weeks thereafter." | ( Abdollahian, E; Azarpazhooh, A; Haghighi, MB; Mokhber, N; Saghebi, A; Samadi, R; Soltanifar, A, 2014) |
| "Research on novel treatments for major depressive disorder focuses quite deeply on glutamate function, and this research would benefit from a brain-imaging technique that precisely quantified glutamate function." | ( Abdallah, CG; De Feyter, HM; Fasula, M; Jiang, L; Krystal, JH; Mason, GF; Rothman, DL; Sanacora, G, 2014) |
| "Patients (N = 245) meeting criteria for major depressive disorder (MDD), diagnosed with DSM-IV-TR, were randomly assigned to double-blind treatment with bupropion extended-release, escitalopram, or the combination." | ( Amat, JA; Blier, P; Gerra, ML; Hellerstein, DJ; Marchesi, C; Stewart, JW, 2014) |
| "In a sample of 34 patients with major depressive disorder, treated with antidepressants, the combined effect of treatment and natural course was examined over a period of 18 weeks with Ecological Momentary Assessment (EMA)." | ( Bakker, RP; Barge, D; Delespaul, P; van Os, J, 2014) |
| "A 41-year-old woman with Major Depressive Disorder-Recurrent was treated with topiramate at 150 mg/day." | ( Aguglia, E; Cinconze, M; Di Giannantonio, M; Marino, M; Martinotti, G; Nasca, MR; Signorelli, MS, 2015) |
| "Approximately 45% of patients with major depressive disorder (MDD) do not remit when treated with biogenic amine antidepressants." | ( Burch, RM; Macaluso, M; Mehra, DO; Moskal, JR; Preskorn, S; Zammit, G, 2015) |
| "Cognitive impairment in major depressive disorder predicts poor treatment outcome, but ABCB1 genetic effects in patients with cognitive impairment are untested." | ( DeBattista, C; Etkin, A; Lazzeroni, LC; Murphy, GM; Schatzberg, AF; Williams, LM, 2015) |
| "When patients with major depressive disorder (MDD) are partial responders to antidepressant therapy, adjunctive treatment with an agent that has a different mode of action may provide additional benefit." | ( Ahl, J; Dellva, MA; Goldberger, C; Greenbaum, M; Oakes, TM; Perahia, DG; Poppe, C; Waterman, K, 2015) |
| "Current treatments for major depressive disorder (MDD) have a time lag and are ineffective for a large number of patients." | ( DiLeone, RJ; Duman, RS; Dwyer, JM; Lepack, AE; Maldonado-Avilés, JG, 2015) |
| "After patients with major depressive disorder (MDD) respond to acute-phase cognitive therapy (CT), continuation-phase treatments may be applied to improve long-term outcomes." | ( Clark, LA; Jarrett, RB; Thase, ME; Vittengl, JR, 2015) |
| "Forty patients diagnosed with a major depressive disorder for which ECT was indicated as a treatment for their current episode were randomly allocated to either the memantine (5mg/day) group or the placebo group." | ( Abbasinazari, M; Adib-Eshgh, L; Beyraghi, N; Dabir, S; Jafari, R; Rostami, A, 2015) |
| "The treatment goal of major depressive disorder (MDD) is achieving and maintaining remission." | ( Barak, Y; Ben-Amnon, Y; Cohen, Y; Klang, SH, 2015) |
| "For 83 patients with major depressive disorder, the treatment response rate and the incidence of adverse drug reaction (ADR) were characterized by logistic regression using daily dose or area under the concentration-time curve (AUC) estimated from the final model as a potential exposure predictor." | ( Chun, MR; Chung, MW; Kim, DK; Kim, HD; Kim, JR; Lee, SY; Lim, SW; Myung, W; Na, HS; Woo, HI, 2015) |
| "Treatment-resistant depression is a major depressive disorder that does not respond to adequate treatment of at least two antidepressants and is one of the major clinical challenges for clinicians and clinical pharmacists." | ( Oravecz, R; Stuhec, M, 2016) |
| "There was no association between major depressive disorder and generalized anxiety disorder and treatment response." | ( A, Y; E, F; GM, Sel-D; H, AG; M, A; MM, B; MM, el-S; U, Y, 2015) |
| "Patients meeting DSM-IV-TR criteria for major depressive disorder who presented with two or three protocol-defined manic symptoms were randomly assigned to 6 weeks of double-blind treatment with either lurasidone at 20-60 mg/day (N=109) or placebo (N=100)." | ( Cucchiaro, J; Loebel, A; Mao, Y; Pikalov, A; Silva, R; Streicher, C; Suppes, T; Targum, S, 2016) |
| "However, the presence of recurrent major depressive disorder and multiple psychiatric comorbidities is associated with poorer functioning trajectories, offering targets for maintenance treatment or secondary prevention." | ( Albano, AM; Curry, JF; Feldhaus, C; Henry, DB; Jacobs, RH; Langenecker, SA; Peters, AT; Reinecke, MA; Silva, SG, 2016) |
| "Youth (aged 8-17 years) with major depressive disorder (MDD) were treated with fluoxetine for 6 weeks." | ( Emslie, GJ; Foxwell, AA; Jones, JM; Kennard, BD; King, J; Mayes, TL; Moore, J; Nakonezny, PA, 2015) |
| "Treatment of major depressive disorder aims for symptom remission and recovery of function, and involves a multifaceted approach including drug therapy, evidence-based psychotherapy, and electroconvulsive therapy, according to disease severity." | ( Coluccia, A; Cuomo, A; De Giorgi, R; Fagiolini, A; Forgione, RN; Goracci, A, 2016) |
| "Many patients with major depressive disorder have treatment-resistant depression, defined as no adequate response to two consecutive courses of antidepressants." | ( Anderson, IM; Ferrier, IN; Finkelmeyer, A; Gallagher, P; Grunze, HC; Haddad, PM; Hughes, T; Lloyd, AJ; Mamasoula, C; McAllister-Williams, RH; McColl, E; Pearce, S; Siddiqi, N; Sinha, BN; Steen, N; Wainwright, J; Watson, S; Winter, FH, 2016) |
| "In treating Major Depressive Disorder with associated painful physical symptoms (PPS), the effect of duloxetine on PPS has been shown to decompose into a direct effect on PPS and an indirect effect on PPS via depressive symptoms (DS) improvement." | ( Fujikoshi, S; Funai, J; Harada, E; Iwata, N; Ossipov, MH; Tokuoka, H; Wohlreich, MM, 2016) |
| "Millions of patients suffer from major depressive disorder (MDD), but many do not respond to selective serotonin reuptake inhibitor (SSRI) therapy." | ( Batzler, A; Bhasin, SS; Biernacka, J; Bobo, WV; Frye, MA; Gupta, M; Hall-Flavin, D; Jenkins, GD; Kaddurah-Daouk, R; Kalari, K; Kubo, M; Liu, D; Matson, W; Mushiroda, T; Nakamura, Y; Neavin, D; Skime, M; Wang, L; Weinshilboum, RM; Zhu, H, 2016) |
| "In the treatment of major depressive disorder (MDD), it is not fully understood how individual symptoms improve over time (trajectory) in remitters." | ( Kuga, A; Ozeki, A; Takahashi, H; Tokuoka, H; Tsuji, T; Wohlreich, MM; Yoshikawa, A, 2016) |
| "The patient was diagnosed with major depressive disorder and was treated with duloxetine." | ( Chang, CC; Hsu, WY; Ma, SP; Tsai, CJ, 2017) |
| "Anxiety symptoms are prevalent in major depressive disorder (MDD) and are associated with greater illness severity, suicidality, impaired functioning and poor response to antidepressant treatment (ADT)." | ( McIntyre, RS; Weiller, E; Weiss, C; Zhang, P, 2016) |
| "Forty-six medication-free patients with major depressive disorder participated in a diffusion tensor imaging scan prior to completing an 8-week treatment regime with citalopram or quetiapine XR." | ( Clark, D; Foster, J; Hall, GB; Ramasubbu, R; Tatham, EL, 2017) |
| "Patients (n = 159) aged ≥60 years had major depressive disorder that failed to remit with venlafaxine monotherapy." | ( Anderson, SJ; Blumberger, DM; Butters, MA; Dew, MA; Diniz, BS; Karp, JF; Lenze, EJ; Lotrich, FE; Mulsant, BH; Reynolds, CF; Smagula, SF; Wallace, ML, 2016) |
| "Up to 30-40 % of the major depressive disorder patients do not respond sufficiently to antidepressant treatment." | ( Adithan, S; Manoharan, A; Rajkumar, RP; Shewade, DG, 2016) |
| "One hundred and two major depressive disorder patients were started on fluoxetine treatment and after 6 weeks, classified as responders (n = 56) and non-responders (n = 46) using Hamilton depression rating scale and genotyped." | ( Adithan, S; Manoharan, A; Rajkumar, RP; Shewade, DG, 2016) |
| "Coexisting anxiety is common in major depressive disorder (MDD) and more difficult to treat than depression without anxiety." | ( Baldwin, DS; Florea, I; Jacobsen, PL; Nomikos, GG; Zhong, W, 2016) |
| "John's wort (SJW) for the treatment of Major Depressive Disorder (MDD)." | ( Apaydin, EA; Booth, MS; Hempel, S; Maher, AR; Miles, JN; Shanman, R; Sorbero, ME, 2016) |
| "Adult outpatients with major depressive disorder were randomly assigned to open or placebo-controlled citalopram treatment." | ( Brown, PJ; Choo, TH; Chung, S; Kirsch, I; Peterson, BS; Roose, SP; Rutherford, BR; Wager, TD; Wall, MM, 2017) |
| "In the treatment of major depressive disorder (MDD) with mixed features, the comparable efficacy of antidepressants versus other treatments, such as SGAs, remains unknown." | ( McIntyre, RS; Rosenblat, JD, 2017) |
| "Approximately 50% of patients with major depressive disorder do not respond adequately to their antidepressant treatment, underscoring the need for more effective treatment options." | ( Baker, RA; Fava, M; Matsushima, Y; Okame, T; Perry, P; Weiller, E, 2017) |
| "In patients with major depressive disorder who had switched to open-label adjunctive brexpiprazole following inadequate response to previous adjunctive or combination therapy, improvements were observed in depressive symptoms, general functioning, cognitive function, and energy/alertness." | ( Baker, RA; Fava, M; Matsushima, Y; Okame, T; Perry, P; Weiller, E, 2017) |
| "Predicting treatment response for major depressive disorder can provide a tremendous benefit for our overstretched health care system by reducing number of treatments and time to remission, thereby decreasing morbidity." | ( Bhaumik, R; Crane, NA; Dion, C; Gowins, JR; Jenkins, LM; Langenecker, SA; Mickey, BJ; Zubieta, JK, 2017) |
| "In treated patients with major depressive disorder (MDD), residual symptoms are common and challenging to disentangle from possible antidepressant side effects." | ( Baer, L; Clain, A; Fava, M; Fisher, L; Freeman, MP; Pooley, J; Rabbitt, R, 2017) |
| "Current pharmacological treatments for major depressive disorder (MDD) are ineffective in a significant proportion of patients, and the identification of new antidepressant compounds has been difficult." | ( Breen, G; Lee, SH; Murphy, T; Powell, TR; Price, J; Thuret, S, 2017) |
| "220 patients with major depressive disorder who were non-responders to a previous antidepressant were treated with venlafaxine for 4-6 weeks and in case of non-response with escitalopram for 4-6 weeks." | ( Albani, D; Calabrò, M; Calati, R; Crisafulli, C; Fabbri, C; Forloni, G; Juven-Wetzler, A; Kasper, S; Martines, R; Mendlewicz, J; Montgomery, S; Serretti, A; Souery, D; Zohar, J, 2017) |
| "At least one-third of patients with major depressive disorder (MDD) have treatment-resistant depression (TRD), defined as lack of response to two or more adequate antidepressant trials." | ( Ahle, G; Charney, DS; Collins, KA; Iosifescu, DV; Kiraly, DD; Murrough, JW; Sayed, S; Soleimani, L; Wade, E; Welch, A, 2017) |
| "In-patients (n = 88) with major depressive disorder were randomized to 7-week treatment with imipramine or venlafaxine (phase I)." | ( Birkenhäger, TK; Hoogendijk, WJG; Kamperman, AM; van den Broek, WW; Vermeiden, M, 2017) |
| "Patients with major depressive disorder (partial responders to ongoing antidepressant therapy) were randomized 1:1 to once-daily oral filorexant 10 mg or matching placebo." | ( Ceesay, P; Connor, KM; Herring, WJ; Hutzelmann, J; Krystal, AD; Lines, C; Michelson, D; Snavely, D; Thase, M; Trivedi, MH, 2017) |
| "Approximately 30-50% of patients with major depressive disorder can be classed as treatment resistant, widely defined as a failure to respond to two or more adequate trials of antidepressants in the current episode." | ( Attenburrow, MJ; Cipriani, A; Cleare, AJ; Dietch, D; Geddes, J; Goldsmith, K; Holland, R; Hutchinson, J; Marwood, L; McAllister-Williams, RH; Nair, R; Pickles, A; Romeo, R; Taylor, R; Young, AH, 2017) |
| "Similar rates of remission from Major Depressive Disorder (MDD) have been documented between ethnic groups in response to antidepressant treatment." | ( Chang, T; Dang, J; Danovitch, I; Ganjian, S; IsHak, WW; López, E; Manier, K; Mirocha, J; Parisi, T; Shapiro, BB; Steiner, AJ; Vanle, B, 2018) |
| "A total of 81 major depressive disorder (MDD) patients (44 patients with treatment-responsive depression (RD) and 37 patients with non-responding depression (NRD)) and 43 healthy controls (HC) underwent resting-state functional magnetic resonance imaging scans and clinical estimates." | ( Gong, L; Hou, Z; Xie, C; Yin, Y; Yuan, Y; Zhang, Y; Zhi, M, 2018) |
| "Patients with major depressive disorder (MDD) who do not adequately respond to antidepressant treatment (ADT) may benefit from adjunctive atypical antipsychotics; however, certain agents target specific symptoms of depression and not the full syndrome." | ( Hobart, M; Nelson, JC; Weiller, E; Weiss, C; Zhang, P, 2018) |
| "An effective rapid-onset treatment for major depressive disorder could save lives." | ( Pergolizzi, JV; Raffa, RB; Taylor, R, 2018) |
| "Response to antidepressant treatment in major depressive disorder (MDD) cannot be predicted currently, leading to uncertainty in medication selection, increasing costs, and prolonged suffering for many patients." | ( Binder, EB; Carrillo-Roa, T; Craighead, WE; Dunlop, BW; Harbich, D; Herzog, DP; Holsboer, F; Labermaier, C; Lareau, C; Mayberg, HS; Müller, MB; Nemeroff, CB; Rex-Haffner, M; Santarelli, S; Scharf, SH; Schmidt, MV; Sillaber, I; Uhr, M; Wagner, KV; Weber, P, 2017) |
| "Metabolic profiles were derived from major depressive disorder subject blood samples collected after ECTP treatment." | ( Bandu, R; Ha, K; Ha, TH; Kim, KP; Kim, SJ; Lee, HJ; Lee, HM, 2018) |
| "Treatment-resistant patients with major depressive disorder (MDD) or bipolar disorder (BD) (n = 126) drawn from three studies received a single subanesthetic (0." | ( Ballard, ED; Brutsche, NE; Farmer, C; Jaso, BA; Luckenbaugh, DA; Niciu, MJ; Park, LT; Shovestul, BJ; Zarate, CA, 2018) |
| "The symptoms of major depressive disorder (MDD) are rapidly alleviated by administration of a single dose of the glutamatergic modulator ketamine." | ( Brutsché, N; Evans, JW; Nugent, AC; Park, LT; Szczepanik, J; Zarate, CA, 2018) |
| "In a sample of 132 outpatients with major depressive disorder (MDD) treated with an SSRI-group antidepressant escitalopram, the Swedish universities Scales of Personality (SSP) were used in order to find predictive personality traits." | ( Aluoja, A; Eller, T; Maron, E; Raag, M; Tõru, I; Võhma, Ü, 2018) |
| "Patients diagnosed with major depressive disorder (MDD) and treated with vortioxetine independently of study enrollment were assessed over 52 weeks at visits that emulated a real-life setting." | ( Bougie, J; Chokka, P; Proulx, J; Rampakakis, E, 2019) |
| "The study compared all-cause and major depressive disorder (MDD)-related healthcare resource use (HRU) and costs in patients with MDD treated with atypical antipsychotic (AAP) adjunctive therapy early or later in treatment." | ( Burudpakdee, C; Greene, M; Hartry, A; Seetasith, A, 2018) |
| "Pharmacological treatment of major depressive disorder (MDD) typically involves a lengthy trial and error process to identify an effective intervention." | ( Aizenstein, HJ; Andreescu, C; Butters, MA; Karim, HT; Karp, JF; Reynolds, CF; Tudorascu, D; Wang, M, 2018) |
| "In patients with major depressive disorder (MDD), antidepressant response and remission rates are low, highlighting the need for new treatment approaches." | ( Baune, BT; Fourrier, C; Mills, NT; Sampson, E, 2018) |
| "Patients with major depressive disorder and inadequate response to antidepressant treatments may experience a prolonged loss of functioning." | ( Eriksson, H; Hobart, M; Meehan, SR; Weiss, C; Zhang, P, 2019) |
| "Patients with Major Depressive Disorder (MDD) who are non-improvers after two weeks of antidepressant treatment have a high risk of treatment failure." | ( Braus, DF; Dreimüller, N; Elsner, S; Engel, A; Lieb, K; Roll, SC; Tadić, A; Wagner, S, 2019) |
| "Thirty-six older major depressive disorder (MDD) patients not currently on antidepressant treatment had a baseline, pre-treatment resting-state functional magnetic resonance imaging scan, followed by sertraline treatment for 12 weeks." | ( Emam, H; Pearlson, GD; Steffens, DC; Wang, L, 2019) |
| "Adults with major depressive disorder frequently do not achieve remission with an initial treatment." | ( Cole, SP; Craighead, WE; Dunlop, BW; Kinkead, B; LoParo, D; Mayberg, HS; Mletzko-Crowe, T; Nemeroff, CB, 2019) |
| "About 20 to 30 percent of patients with Major Depressive Disorder (MDD) do not respond to standard treatment and are considered treatment-resistant." | ( Aust, S; Bajbouj, M; Basso, L; Chae, WR; Cosma, NC; Gärtner, M; Grimm, S; Heuser-Collier, I; Otte, C; Regen, F; van Hall, F; Wingenfeld, K, 2019) |
| "An 18-year-old female diagnosed with major depressive disorder (MDD) was treated with 100 mg sertraline once daily." | ( Liu, QS; Luo, T; Wei, B; Yang, YJ, 2019) |
| "Almost two-thirds of patients with major depressive disorder do not achieve remission with initial treatments." | ( Chen, P; Davis, L; Hicks, P; Johnson, GR; Mohamed, S; Tal, I; Thase, M; Vertrees, J; Zhao, Y; Zisook, S, 2019) |
| "Outpatients (ages 18-65 years) with major depressive disorder and a current depressive episode (Montgomery Åsberg Depression Rating Scale total score ≥30) were randomized to an initial single dose of either intravenous vortioxetine 17 mg (n = 27) or intravenous placebo (n = 28), both treatments followed by 2 weeks of oral vortioxetine (10 mg/day)." | ( Areberg, J; Ettrup, A; Florea, I; Schmidt, SN; Vieta, E, 2019) |
| "Although pharmacogenetics for major depressive disorder (MDD) is gaining momentum, the role of genetics in differences in response to antidepressant treatment is controversial, as they depend on multifactorial and polygenic phenotypes." | ( Arranz, MJ; Carceller-Sindreu, M; de Diego-Adeliño, J; Draganov, M; Gallego-Fabrega, C; Jubero, M; Portella, MJ; Salazar, J, 2019) |
| "The neurobiology of major depressive disorder (MDD) remains incompletely understood, and many individuals fail to respond to standard treatments." | ( Anderson, R; Barnett, AJ; Cash, RFH; Cocchi, L; Fitzgerald, PB; Kucyi, A; Rogachov, A; Zalesky, A, 2019) |
| "In patients with Major Depressive Disorder (MDD), we studied the interactive effects of age and cortisol in association with MDD diagnostic status and mood and memory response to antidepressant treatment." | ( Connolly, CG; Hough, CM; Jain, FA; Mackin, S; Mellon, SH; Meyerhoff, DJ; Morford, A; Reus, VI; Wolkowitz, OM; Yang, TT, 2019) |
| "Medications to treat major depressive disorder (MDD) are not equally effective across patients." | ( Adams, P; Almeida, JR; Aslam, H; Carmody, T; Chase, HW; Cooper, C; Deckersbach, T; Fava, M; Fournier, JC; Greenberg, T; Kurian, B; McGrath, PJ; McInnis, MG; Oquendo, MA; Parsey, R; Peltier, S; Phillips, ML; Stiffler, R; Toups, MS; Trivedi, M; Weissman, M, 2020) |
| "Improvement of depressive symptoms in major depressive disorder patients treated with vortioxetine was associated with significant improvements in sleep." | ( Cao, B; Chen, Y; Iacobucci, M; Lee, Y; Mansur, RB; McIntyre, RS; Park, C; Rosenblat, JD; Subramaniapillai, M; Zuckerman, H, 2019) |
| "For the adjunctive treatment of major depressive disorder, phase 3 studies are in progress." | ( Barabassy, A; Kapas, M; Kiss, B; Laszlovszky, I; Nemeth, G, 2019) |
| "In treating major depressive disorder, we lack tests anchored in neurobiology that predict antidepressant efficacy." | ( Goldstein-Piekarski, AN; Korgaonkar, MS; Tozzi, L; Williams, LM, 2020) |
| "Although major depressive disorder (MDD) is associated with altered functional coupling between disparate neural networks, the degree to which such measures are ameliorated by antidepressant treatment is unclear." | ( Fornito, A; Goldstein-Piekarski, AN; Korgaonkar, MS; Williams, LM, 2020) |
| "195 Chinese Han major depressive disorder (MDD) patients were recruited and received a 6-week venlafaxine treatment in this study." | ( Bi, Y; Guo, Z; He, G; He, L; Li, X; Ma, G; Niu, W; Ren, D; Shi, L; Sun, Q; Wu, X; Xu, F; Yang, F; Yu, T; Yuan, F; Yuan, R; Zhu, Y, 2020) |
| "The response of patients with major depressive disorders (MDD) to antidepressant treatments have been shown to be affected by multiple factors, including disease severity and inflammation." | ( Drevets, W; Li, QS; Sun, Y; Turecki, G, 2020) |
| "Nearly 1 in 3 patients with major depressive disorder who respond to antidepressants relapse within 6 months of treatment discontinuation." | ( Berwian, IM; Collins, AGE; Huys, QJM; Seifritz, E; Stephan, KE; Walter, H; Wenzel, JG, 2020) |
| "Lithium has been used to treat major depressive disorder, yet the neural circuit mechanisms underlying this therapeutic effect remain unknown." | ( Cao, JL; Ding, HL; Han, MH; Hu, SW; Liu, D; Liu, H; Montgomery, SE; Song, SP; Tang, QQ; Wang, D; Wang, ZY; Xu, Z; Yang, JX; Yang, XN; Zhang, H, 2020) |
| "The treatment of major depressive disorder (MDD) is still a challenge." | ( de Almeida, RF; Elisabetsky, E; Pocharski, CB; Rodrigues, ALS; Souza, DO, 2020) |
| "Sertraline in the treatment of Major Depressive Disorder (MDD) in South Korean participants." | ( Choi, WJ; Kim, B; Kim, S; Kim, WJ; Park, JY; Park, S; Roh, D; Son, SJ, 2020) |
| "A total of 116 participants with major depressive disorder treated with sertraline in stage 1 served as an independent replication sample." | ( Adams, P; Almeida, J; Ang, YS; Bruder, G; Carmody, T; Chase, HW; Chin Fatt, CR; Cooper, CM; Deckersbach, T; Deldin, P; Fava, M; Kaiser, R; McGrath, P; McInnis, MG; Oquendo, MA; Parsey, R; Phillips, ML; Pizzagalli, DA; Trivedi, MH; Webb, CA; Weissman, M, 2020) |
| "Participants with major depressive disorder were randomized in a 1:1:1 ratio to undergo 8 weeks of treatment with escitalopram oxalate (n = 162), sertraline hydrochloride (n = 176), or extended-release venlafaxine hydrochloride (n = 180)." | ( Basu, S; Dass, N; Irvin, J; Keller, AS; Ng, A; Rajpurkar, P; Taylor, Z; Vale, V; Williams, LM; Yang, J, 2020) |
| "Fifty-one females with major depressive disorder or anxiety disorder were stratified into three groups: 1) those treated with SSRIs <23 years of age, 2) those treated with SSRIs >23 years of age, and 3) those that were never treated with SSRIs." | ( Homberg, JR; Lucassen, PJ; Reneman, L; Schrantee, A; Solleveld, MM, 2020) |
| "A sample of 46 older adults with major depressive disorder received 12 weeks of escitalopram treatment at a daily target dose of 20 mg." | ( Alexopoulos, GS; Bress, JN; Gunning, FM; Hoptman, MJ; Kanellopoulos, T; Oberlin, L; Pimontel, MA; Solomonov, N, 2021) |
| "Despite the growing burden of major depressive disorder (MDD) on the society, therapeutic management that is mostly based on the conventional monoaminergic mechanisms, is significantly delimited especially from low response rate and time lag for treatment response; thus, often prolonging the distress for patients." | ( Chakravarty, S; K V, A; Mohan, AS, 2020) |
| "Sixty patients with major depressive disorder were randomly assigned to either eight training sessions of feedback-based gaze-contingent music reward therapy designed to divert patients' gaze toward positive over sad stimuli, or to a control condition which entailed eight sessions of gaze-noncontingent music." | ( Bar-Haim, Y; Lazarov, A; Pine, DS; Shamai-Leshem, D, 2021) |
| "Patients with major depressive disorder (MDD) having active suicidal ideation with intent require immediate treatment." | ( Canuso, CM; Drevets, WC; Fu, DJ; Hough, D; Ionescu, DF; Kasper, S; Lane, R; Lim, P; Manji, H; Qiu, X, 2021) |
| "Adolescents with major depressive disorder (n = 36) received CBT and completed a reward task at 3 time points (pretreatment, midtreatment and posttreatment) while 128-channel electroencephalographic data were acquired." | ( Appleman, L; Auerbach, RP; Bondy, E; Pizzagalli, DA; Stanton, CH; Webb, CA, 2021) |
| "Since about one-third of patients with major depressive disorder (MDD) do not respond adequately to available antidepressants, there is a need for treatments based on novel mechanisms of action." | ( Berg, E; Charney, DS; Mathé, AA; Michaneck, M; Murrough, JW, 2020) |
| "A group of six European experts in major depressive disorder (MDD) and TRD, with clinical experience of treating patients with esketamine nasal spray, first generated practical recommendations, before editing and voting on these to develop consensus statements during an online meeting." | ( Cubała, WJ; Fagiolini, A; Kasper, S; Ramos-Quiroga, JA; Souery, D; Young, AH, 2021) |
| "Patients with major depressive disorder often have limited response to first-line and second-line medications; hence, novel pharmacological treatments are needed for treatment-resistant depression (TRD)." | ( Beaulieu, S; Blier, J; Blier, P; Brietzke, E; Frey, BN; Kennedy, SH; Lam, RW; McGirr, A; McIntyre, RS; Milev, RV; Parikh, SV; Ravindran, AV; Ravindran, N; Richard-Devantoy, S; Schaffer, A; Swainson, J; Taylor, VH; Tourjman, V; van Ameringen, M; Yatham, LN, 2021) |
| "Treatment for major depressive disorder (MDD) is imprecise and often involves trial-and-error to determine the most effective approach." | ( Alschuler, DM; Ang, YS; Bruder, GE; Carmody, T; Cooper, CM; Cusin, C; Deldin, P; Fava, M; Keilp, JG; McGrath, PJ; McInnis, MG; Oquendo, MA; Parsey, R; Pechtel, P; Pizzagalli, DA; Rutherford, A; Trivedi, MH; Webb, CA; Weissman, M, 2022) |
| "In patients with major depressive disorder (MDD), poor antidepressant treatment response might be associated with an excessive body mass index (BMI)." | ( Chen, RS; Galling, B; Wang, G; Xiao, L; Zhou, J, 2021) |
| "Patients with major depressive disorder who do not respond to ≥2 different pharmacological treatments within the current depressive episode are considered to have treatment resistant depression (TRD)." | ( Blackowicz, M; Cooper, K; Drevets, WC; Fedgchin, M; Floden, L; Hudgens, S; Jamieson, C; Lane, R; Popova, V; Singh, J, 2021) |
| "This study included 127 patients with major depressive disorder or bipolar disorder who received ketamine treatments during a 12-day period." | ( Lan, X; Liu, W; Ning, Y; Wang, C; Wang, M; Zhan, Y; Zhang, B; Zheng, W; Zhou, Y, 2021) |
| "Treatment-seeking individuals with major depressive disorder (MDD), anxiety disorders, and/or SUD (N = 160; 80 % with MDD) recruited into the Tulsa 1000 study provided blood samples, participated in clinical interviews, and completed a questionnaire battery querying symptoms of current psychopathology and emotional processing." | ( Burrows, K; Ekhtiari, H; Figueroa-Hall, LK; Kirlic, N; May, AC; Paulus, MP; Savitz, J; Smith, R; Stewart, JL; White, EJ, 2021) |
| "Many individuals with major depressive disorder (MDD) do not respond to initial antidepressant monotherapy." | ( Bhat, V; Chakrabarty, T; Frey, BN; Giacobbe, P; Kennedy, SH; Lam, RW; Lou, W; Michalak, EE; Milev, RV; Morton, E; Müller, DJ; Parikh, SV; Rotzinger, S, 2021) |
| "We describe a case of a patient with major depressive disorder (MDD) and acute suicidality who achieved rapid remission following three treatments with intranasal racemic ketamine." | ( Halpape, K; Peters, E; Wanson, A; Ziegler, L, 2021) |
| "The large percentage of adults with major depressive disorder (MDD) insufficiently responding and/or tolerating conventional monoamine-based antidepressants invites the need for mechanistically novel treatments." | ( Cao, B; Ho, R; Majeed, A; McIntyre, RS; Ng, J; Phan, L; Rosenblat, JD; Teopiz, KM; Xiong, J, 2021) |
| "Bupropion is an effective treatment for major depressive disorder and smoking cessation." | ( Çim, EFA; Kamış, GZ; Kurhan, F, 2021) |
| "Successful treatment of major depressive disorder (MDD) can be challenging, and failures ("treatment-resistant depression" [TRD]) are frequent." | ( Bahji, A; Baldessarini, RJ; Tondo, L; Undurraga, J; Vázquez, GH, 2021) |
| "A proportion of individuals with major depressive disorder (MDD) do not receive adequate therapeutic benefit from conventional monoaminergic antidepressant drugs, leading to treatment-resistant depression (TRD)." | ( Di Vincenzo, JD; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Mansur, R; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "Treatment of major depressive disorder (MDD) including treatment-resistant depression (TRD) remains a major unmet need." | ( Dome, P; Gonda, X; Neill, JC; Tarazi, FI, 2023) |
| "Treatment effectiveness for major depressive disorder (MDD) is often affected by client non-adherence, dropout, and non-response." | ( Abelson, J; Akeman, E; Aupperle, RL; Bodurka, J; Cannon, MJ; Clausen, A; Craske, MG; Kirlic, N; Kuplicki, R; Martell, C; Mayeli, A; McDermott, TJ; Nacke, M; Paulus, MP; Santiago, J; Stewart, JL; Touthang, J; White, EJ; Wolitzky-Taylor, K; Zoubi, OA, 2021) |
| "Maintenance therapy for major depressive disorder (MDD) is typically recommended at the dose on which the patient was stabilized." | ( Hanson, E; Jacobsen, PL; Murthy, NV; Thase, ME; Tolkoff, M; Xu, R, 2022) |
| "The pharmacological treatment of major depressive disorder with currently available antidepressant drugs is still unsatisfying as response to medication is delayed and in some patients even non-existent." | ( Dahlmanns, JK; Dahlmanns, M; Groemer, TW; Kornhuber, J; Trepl, J, 2022) |
| "Recent trials with psychedelics in major depressive disorder and treatment-resistant depression showed remarkable improvements in depressive symptoms that can last for up to several months after even a single administration." | ( Hillhouse, TM; Magaraggia, I; Porter, JH; Schreiber, R; van den Berg, M, 2022) |
| "Current first-line treatments for major depressive disorder (MDD), i." | ( Ahmadalipour, A; Fakhari, A; Khajehnasiri, N; Pakkhesal, S; Sharafi, A, 2022) |
| "The use of psilocybin as treatment for major depressive disorder (MDD) has been examined as a promising alternative to traditional first-line options." | ( Castle, D; Cha, DS; Gill, B; Gill, H; Mansur, RB; Marks, CA; McIntyre, RS; Patel, P; Puramat, P; Rodrigues, NB; Rosenblat, JD, 2022) |
| "Discovering biomarkers of major depressive disorder (MDD) can give a deeper understanding of this mood disorder and improve the ability to screen for, diagnose, and treat MDD." | ( Beškoski, V; Filipović, D; Lješević, M; Nikolić, M; Perić, I, 2022) |
| "One hundred one patients with major depressive disorder were randomized at baseline to receive either mirtazapine or SSRI treatment." | ( Bandou, H; Kato, M; Kinoshita, T; Koshikawa, Y; Naito, M; Nishida, K; Sakai, S; Takekita, Y, 2022) |
| "One goal of research into major depressive disorder (MDD) is to develop markers to predict and monitor the response to psychotropic treatments." | ( Angioi-Duprez, K; Cosker, E; Laprévote, V; Moulard, M; Schwan, R; Schwitzer, T, 2022) |
| "Pharmacological treatment of major depressive disorder is often inefficient, and multiple strategies are used for inadequate response to antidepressants." | ( Chen, B; Ma, X; Wang, M; Yan, Y; Yang, X; Yin, L, 2022) |
| "Psychedelic therapy shows promise for Major Depressive Disorder, especially when treatment-resistant, as well as life-threatening illness distress." | ( Cleare, AJ; Ko, K; Kopra, EI; Rucker, JJ, 2023) |
| "The positive effects of BUP XL on major depressive disorder treatment are well-reported, but few reports are on the pharmacokinetics of BUP XL in prisons." | ( Oravecz, R; Stuhec, M, 2022) |
| "We collected a clinical test sample of Major Depressive Disorder (MDD) patients treated with vortioxetine (N = 907) or placebo (N = 455) from seven randomized, double-blind, clinical trials." | ( Albrechtsen, A; Dalby, M; Forsingdal, A; Howes, OD; Moltke, I; Nøhr, AK; Vitezic, M, 2022) |
| "Approximately 15% of patients with major depressive disorder are refractory to currently available treatments." | ( Brent, DA; Finegold, DN; Hughes, M; Hyland, K; Naviaux, RK; Pan, LA; Peters, DG; Segreti, AM; Shaw, A; Vockley, J; Wrobleski, J, 2023) |
| "Eighteen adults age ≥ 60 with major depressive disorder recruited for a larger randomized controlled trial received 9 weeks of Problem-Solving Therapy or Engage therapy." | ( Alexopoulos, GS; Arader, L; Areán, PA; Bress, JN; Gunning, FM, 2023) |
| "Pharmacotherapy for major depressive disorder (MDD) typically consists of trial-and-error and clinician preference approaches, where patients often fail one or more antidepressants before finding an optimal regimen." | ( Amin, NS; Arwood, MJ; Cambridge, MD; Michaud, V; Russell, J; Toro-Pagán, NMD; Turgeon, J, 2023) |
| "The pathophysiology of major depressive disorder (MDD) is diverse and multi-factorial, yet treatment strategies remain limited." | ( Hen-Shoval, D; Indig-Naimer, T; Kogan, NM; Mechoulam, R; Moshe, L; Shoval, G; Weller, A; Zalsman, G, 2023) |
| "One in three adults with major depressive disorder (MDD) do not experience clinically significant improvement after multiple sequential courses of antidepressants and have treatment-resistant depression (TRD)." | ( Jha, MK; Mathew, SJ, 2023) |
| "Currently, major depressive disorder (MDD) treatment plans are based on trial-and-error, and remission rates remain low." | ( Arns, M; Enriquez-Geppert, S; Gevirtz, R; Gordon, E; Sack, AT; van der Vinne, N; van Dijk, H; Zwienenberg, L, 2023) |
| "Digital phenotyping in patients with major depressive disorder will aid in the timely prediction of treatment effectiveness." | ( Lin, CH; Tsai, HJ; Tsai, SJ; Yang, AC; Yang, WC, 2023) |
| "Unsatisfactory responses to major depressive disorder (MDD) therapeutics available necessitated up-to-date treatment approaches." | ( A Basti, F; Akhondzadeh, S; Arab Bafrani, M; Asadigandomani, H; Kafi, F; Shamabadi, A, 2023) |
| "Treatment effect in clinical trials for major depressive disorders (RCT) can be viewed as the resultant of treatment specific and non-specific effects." | ( Bressolle-Gomeni, F; Fava, M; Gomeni, R, 2023) |
| "Guidance on Major Depressive Disorder (MDD) treatment in those with comorbid Alcohol Use Disorder (AUD) is limited." | ( Blumberger, DM; Daskalakis, ZJ; Jones, BDM; Le Foll, B; Sloan, ME; Tang, VM; Voineskos, D; Wang, G; Weissman, CR; Yu, D, 2023) |
| "Eleven participants with major depressive disorder received 10 days iTBS treatment." | ( Chen, X; Luo, X; Yuan, S; Zhang, B; Zhou, Y, 2023) |
| "Treatment response and resistance in major depressive disorder (MDD) are suggested to be heritable." | ( Andersson, E; Boberg, J; Clements, CC; Jonsson, L; Karlsson, R; Kowalec, K; Landén, M; Lewis, CM; Lu, Y; Rück, C; Sigström, R; Song, J; Sullivan, PF; Xiong, Y, 2023) |
| "A significant proportion of adults with major depressive disorder (MDD) do not respond to treatments which are currently used in clinical practice such as first-generation monoamine-based antidepressants." | ( Akbar, D; Cao, B; Ceban, F; Ho, R; Kwan, ATH; McIntyre, RS; Rhee, TG; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2023) |
| "Adolescent major depressive disorder (MDD) is a prevalent mental health problem with low treatment success rates." | ( Chen, F; Gan, X; He, Y; Huang, Y; Lei, T; Li, J; Li, X; Liu, R; Ouyang, X; Teng, T; Wang, T; Xie, Y; Zhou, X, 2023) |
| "Generalized anxiety disorder and major depressive disorder often benefit from medication and psychotherapy." | ( Benitah Bulbarelli, EM; Chauhan, M; Clapp, AD; Ismaeel, O; Niazi, SK; Nishi, LM; Pujalte, GGA; Shahsamand, A; Yazeji, J, 2023) |